Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Synthesis of 2,6-disubstituted pyridin-3-yl C-2′-deoxyribonucleosides through chemoselective transformations of bromo-chloropyridine C-nucleosides

Tomáš Kubelkaa, Lenka Slavětínskáa, Václav Eignera and Michal Hocek*ab
aInstitute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead & IOCB Research Center, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic. E-mail: hocek@uochb.cas.cz; Tel: +420 220183324
bDepartment of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, CZ-12843 Prague 2, Czech Republic

Received 17th April 2013, Accepted 20th May 2013

First published on 23rd May 2013


Abstract

2-Bromo-6-chloro- and 6-bromo-2-chloropyridin-3-yl deoxyribonucleosides were prepared by the Heck coupling of bromo-chloro-iodopyridines with TBS-protected deoxyribose glycal. Some of their Pd-catalyzed cross-coupling reactions proceeded chemoselectively at the position of the bromine, whereas nucleophilic substitutions were unselective and gave mixtures of products. The mono-substituted intermediates were used for another coupling or nucleophilic substitution giving rise to a small library of title 2,6-disubstituted pyridine C-deoxyribonucleosides. The title nucleosides did not exert antiviral or cytostatic effects.


Introduction

C-Nucleosides are important analogues of natural nucleosides useful for many applications in medicinal chemistry and chemical biology.1 Diverse aryl and hetaryl-C-2′-deoxyribonucleosides were extensively studied as candidates for novel base-pairs in the quest for extension of the genetic alphabet and some of their artificial base-pairs were efficiently replicated by DNA polymerases with high fidelity.2 Moreover, some pyridine C-nucleosides have been used as probes for studying the mechanism of polymerases.3 Most of the current approaches to the synthesis of C-nucleosides suffer from moderate efficiency and/or stereoselectivity.1 Our group has developed a modular approach4 based on the synthesis of halogenated (het)aryl C-nucleoside intermediates and their functionalization by Pd-catalyzed cross-couplings, aminations, carbonylations or hydroxylations. Very recently, the same approach was used even for the functionalization of C-nucleoside triphosphate derivatives.5 Apart from the variation of one substituent, the synthesis of a 2D library of 2,4-disubstituted pyrimidin-5-yl C-2′-deoxyribonucleosides has been developed6 through two consecutive regioselective cross-coupling reactions of the corresponding 2,4-dichloropyrimidine C-nucleoside intermediate. Here we report on the synthesis of a series of 2,6-disubstituted pyridine C-nucleosides.

Results and discussion

In our previous synthesis of 2,4-disubstituted pyrimidine C-nucleosides,6 we have advantageously used the different reactivities of the two chlorines in 2,4-dichloropyrimidine for regioselective reactions. However, in the analogous 2,6-dichloropyridine C-nucleosides, the reactivity of the chlorines is comparable and thus no selectivity would be expected. Therefore our strategy for the target 2,6-disubstituted pyridin-3-yl C-2′-deoxyribonucleosides was based on chemoselective transformations7,8 of either 2-bromo-6-chloro- or 6-bromo-2-chloropyridin-3-yl C-deoxyribonucleoside intermediates.

The synthesis of both bromo-chloropyridine C-nucleoside intermediates started from 3′-O-TBS-protected glycal 1 which can be easily prepared in three steps from thymidine.9 The Heck coupling of 6-bromo-2-chloro-3-iodopyridine with glycal 1 in the presence of Pd(OAc)2, tris(pentafluorophenyl)phosphine and silver carbonate was performed in freshly distilled chloroform at 70 °C (Scheme 1). After 10 hours all starting material was consumed and, because partial desilylation was observed by TLC, the crude reaction mixture was directly treated with Et3N·3HF in THF to give fully deprotected ketone 2 in 52% yield (for two steps) as a pure β-anomer. The subsequent stereoselective reduction of 2 by NaBH(OAc)3 proceeded smoothly giving rise to the desired C-2′-deoxyribonucleoside intermediate 3 in very good 85% yield. The crystal structure of 6-bromo-2-chloropyridine C-nucleoside 3 was determined by X-ray diffraction, which independently confirmed its β-configuration (Fig. 1). Re-protection of 3 by treatment with TBSCl gave the silylated C-nucleoside 4 in 78% yield. An analogous Heck coupling of 1 with 2-bromo-6-chloro-3-iodopyridine under the same conditions as above gave regioisomeric ketone 5 in 59% yield (for two steps) (Scheme 1). Subsequent reduction by NaBH(OAc)3 afforded C-2′-deoxyribonucleoside 6 in 87% yield, which was again silylated to give the desired protected nucleoside intermediate 7 in excellent 92% yield.


Reagents and conditions: (i) 1. Pd(OAc)2, (PhF5)3P, Ag2CO3, CHCl3, 70 °C, 10 h; 2. Et3N·3HF, THF, rt, 15 min; (ii) NaBH(OAc)3, AcOH, CH3CN, 0 °C, 5 min; (iii) TBSCl, imidazole, DMF, rt, 14 h.
Scheme 1 Reagents and conditions: (i) 1. Pd(OAc)2, (PhF5)3P, Ag2CO3, CHCl3, 70 °C, 10 h; 2. Et3N·3HF, THF, rt, 15 min; (ii) NaBH(OAc)3, AcOH, CH3CN, 0 °C, 5 min; (iii) TBSCl, imidazole, DMF, rt, 14 h.

Crystal structures of compounds (a) 3 (CCDC 927315) and (b) 8b (CCDC 927314).
Fig. 1 Crystal structures of compounds (a) 3 (CCDC 927315) and (b) 8b (CCDC 927314).

Having the free (3 and 6) as well as the protected (4 and 7) key bromo-chloropyridine C-nucleoside intermediates, we investigated the chemoselectivity of cross-coupling reactions and nucleophilic substitutions. The bromine atom should be more reactive than chlorine but, on the other hand, steric and other factors can also play a role.

The cross-coupling of protected 6-bromo-2-chloropyridine C-nucleoside 4 with 1.1 equiv. of Me3Al in the presence of Pd(PPh3)4 proceeded chemoselectively to give 2-chloro-6-methylpyridine 8a as the only product in excellent 87% yield (Scheme 2). When the same reaction was performed with 4 equiv. of Me3Al and prolonged reaction time, the product of disubstitution 9a was isolated in 80% yield. Deprotection of 8a and 9a with Et3N·3HF afforded free C-nucleosides 8b (89%) and 9b (88%). The structure of free 2-chloro-6-methylpyridine C-nucleoside 8b was also confirmed by X-ray analysis (Fig. 1). In contrast, cross-coupling of the isomeric 2-bromo-6-chloropyridine intermediate 7 with 1.1 equivalents of Me3Al was completely nonselective and only an unseparable mixture of the starting compound and both products of mono-substitution was obtained.


Reagents and conditions: (i) 1.1 equiv. Me3Al, Pd(PPh3)4, heptane, 70 °C, 3 h; (ii) 4 equiv. Me3Al, Pd(PPh3)4, heptane, 70 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) 1. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 90 °C; 2. NH3, MeOH, rt, 30 min; (v) LiN(SiMe3)2, Ph3SiNH2, CyJohnPhos, Pd2(dba)3, THF, 50 °C, 3 h; (vi) MeONa, MeOH, 120 °C, 10 d; (vii) KOH, t-butyl-XPhos, Pd2dba3, 100 °C.
Scheme 2 Reagents and conditions: (i) 1.1 equiv. Me3Al, Pd(PPh3)4, heptane, 70 °C, 3 h; (ii) 4 equiv. Me3Al, Pd(PPh3)4, heptane, 70 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) 1. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 90 °C; 2. NH3, MeOH, rt, 30 min; (v) LiN(SiMe3)2, Ph3SiNH2, CyJohnPhos, Pd2(dba)3, THF, 50 °C, 3 h; (vi) MeONa, MeOH, 120 °C, 10 d; (vii) KOH, t-butyl-XPhos, Pd2dba3, 100 °C.

Mono-methylated 2-chloropyridine nucleoside 8a was used for a series of follow-up transformations (Scheme 2). The Sonogashira cross-coupling with trimethylsilylacetylene catalyzed by Pd(PPh3)2Cl2 followed by ammonolysis afforded 2-ethynyl-6-methylpyridine C-nucleoside 10a (56%). Pd-catalyzed Hartwig–Buchwald amination10 with a mixture of LiN(SiMe3)2 and Ph3SiNH2 gave 2-amino-6-methylpyridine C-nucleoside 11a in 68% yield. Deprotection of silylated intermediates 10a and 11a furnished free C-nucleosides 10b (65%) and 11b (82%). The reaction of unprotected 2-chloro-6-methylpyridine C-nucleoside 8b with sodium methoxide in MeOH was very sluggish (full conversion was accomplished only after 10 days of heating at 120 °C) but finally gave 2-methoxy-6-methylpyridine C-nucleoside 12 in good 77% yield. Attempted Pd-catalyzed hydroxylation11 using KOH and t-butyl-XPhos did not proceed and only the starting compound and some degradation products were observed (probably due to instability of the pyridone product4f).

The Suzuki–Miyaura cross-coupling of 2-bromo-6-chloropyridine C-nucleoside 7 with 0.9 equivalent of phenylboronic acid in the presence of Ph(PPh3)4 at 60 °C proceeded chemoselectively at position 2 by displacement of the bromine to afford 6-chloro-2-phenylpyridine C-nucleoside 13a in 63% yield (Scheme 3). When we used 3 equiv. of phenylboronic acid and increased the temperature to 100 °C, 2,6-diphenylpyridine C-nucleoside 14a was obtained as a product of double substitution in excellent 95% yield. An analogous reaction of regioisomeric 6-bromo-2-chloropyridine C-nucleoside 4 with 1 equiv. of phenyl boronic acid afforded an unseparable mixture of the starting compound with the product of substitution of the bromine atom at position 6. Silylated nucleosides 13a and 14a were deprotected using Et3N·3HF to obtain free C-nucleosides 13b (91%) and 14b (81%).


Reagents and conditions: (i) 0.9 equiv. PhB(OH)2, Pd(PPh3)4, K2CO3, PhMe, 60 °C, 12 h; (ii) 3 equiv. PhB(OH)2, Pd(PPh3)4, K2CO3, PhMe, 100 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) LiN(SiMe3)2, CyJohnPhos, Pd2(dba)3, THF, 60 °C, 12 h; (v) Pd(PPh3)4, Me3Al, THF, 70 °C, 12 h.
Scheme 3 Reagents and conditions: (i) 0.9 equiv. PhB(OH)2, Pd(PPh3)4, K2CO3, PhMe, 60 °C, 12 h; (ii) 3 equiv. PhB(OH)2, Pd(PPh3)4, K2CO3, PhMe, 100 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) LiN(SiMe3)2, CyJohnPhos, Pd2(dba)3, THF, 60 °C, 12 h; (v) Pd(PPh3)4, Me3Al, THF, 70 °C, 12 h.

Mono-substituted 6-chloro-2-phenylpyridine C-nucleoside 13a was then used for subsequent cross-coupling reactions. Hartwig–Buchwald amination with LiN(SiMe3)2 gave 6-amino-2-phenylpyridine C-nucleoside 15a in excellent 91% yield. Cross-coupling with trimethylaluminum afforded 6-methyl-2-phenylpyridine C-nucleoside 16a in excellent 91% yield. Deprotection of silylated intermediates gave free C-nucleosides 15b (67%) and 16b (85%).

In order to introduce amino or methoxy groups, we have studied the reactivity of intermediates 3 and 6 in nucleophilic substitutions. Our previous studies6 showed good regioselectivity of nucleophilic aminations of 2,4-dichloropyrimidine C-nucleoside. Therefore, we tested reactions of 3 or 6 with methanolic ammonia or copper(I)-catalyzed reaction with liquid ammonia12 in an autoclave using temperatures up to 120 °C but in all cases only the starting material was recovered and we did not observe any reaction. Surprisingly, attempted Buchwald–Hartwig aminations of protected intermediates 4 or 7 did not work either. Nucleophilic substitution of 6 with NaOMe proceeded only at elevated temperature (80 °C) to give an unseparable mixture of the starting compound and both mono-substituted derivatives. The same reaction at higher temperature (120 °C) led to complex mixtures. It seems that the mono-substituted intermediates (containing an electron-donating substituent) are deactivated for another nucleophilic substitution.

Next we studied nucleophilic substitutions with sodium methanethiolate (Scheme 4). The reaction of silylated intermediate 4 with 10 equivalents of NaSMe in DMF at 80 °C led to double substitution with simultaneous deprotection (due to basic conditions) affording 2,6-bis(methylsulfanyl)pyridine C-nucleoside 17 in good 79% yield. The reaction of 4 with 1.2 equivalents of sodium methanethiolate at rt in DMF gave a mixture of both mono-substituted derivatives 18a and 19a in the ratio ca. 1[thin space (1/6-em)]:[thin space (1/6-em)]1. Luckily, we were able to separate them using the flash purification system with a very slow gradient of hexanes to 1% EtOAc in hexanes to obtain 2-chloro-6-(methylsulfanyl)pyridine C-nucleoside 18a (48%) and 6-bromo-2-(methylsulfanyl)pyridine C-nucleoside 19a (43%). Pd-catalyzed methylation of compounds 18a or 19a with trimethylaluminum gave two regioisomeric methyl-(methylsulfanyl)pyridine C-nucleosides 20a (49%) and 21a (58%). All silylated compounds were deprotected to afford free C-nucleosides 18b–21b.


Reagents and conditions: (i) MeSNa 10 equiv., DMF, 80 °C, 12 h; (ii) MeSNa 1.2 equiv., DMF, rt, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) Me3Al, Pd(PPh3)4, 90 °C, 12 h.
Scheme 4 Reagents and conditions: (i) MeSNa 10 equiv., DMF, 80 °C, 12 h; (ii) MeSNa 1.2 equiv., DMF, rt, 12 h; (iii) Et3N·3HF, THF, rt, 14 h; (iv) Me3Al, Pd(PPh3)4, 90 °C, 12 h.

Attempted Sonogashira chemoselective cross-couplings of 4 with (trimethylsilyl)acetylene (TMSA) (Scheme 5) were very difficult to perform since the desired 2-chloro-6-(TMS-ethynyl)pyridine C-nucleoside was unseparable from starting intermediate 4. Finally, we found out that Sonogashira cross coupling with 1 equiv. of trimethylsilylacetylene catalyzed by Pd(PPh3)2Cl2 followed by direct amonolysis gave us a separable mixture of starting compound 4 (37%) and desired product 22a in acceptable 53% yield. When we performed the same reaction with the excess of trimethylsilylacetylene (10 equiv.) and increased the temperature to 90 °C, the product of disubstitution, protected 2,6-bis(ethynyl)pyridine C-nucleoside 23a, was isolated in excellent 95% yield. In order to convert the ethynyl groups to acetyl, we have prepared partially and fully deprotected bis(ethynyl)pyridine C-nucleosides 23b and 23c and attempted a gold catalyzed hydration of the triple bond.13 Unfortunately, only deprotection was observed despite having tried many different conditions.


Reagents and conditions: (i) 1. 1 equiv. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 60 °C; 2. NH3, MeOH, rt, 30 min; (ii) 10 equiv. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 90 °C; (iii) Et3N·3HF, THF, rt, 14 h; (iv) NH3, MeOH, rt, 30 min; (v) NaAuCl4, MeOH, H2O, 80 °C, 6–72 h; (vi) TBAF, THF, rt, 12 h.
Scheme 5 Reagents and conditions: (i) 1. 1 equiv. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 60 °C; 2. NH3, MeOH, rt, 30 min; (ii) 10 equiv. TMSA, Pd(PPh3)2Cl2, CuI, Et3N, DMF, 90 °C; (iii) Et3N·3HF, THF, rt, 14 h; (iv) NH3, MeOH, rt, 30 min; (v) NaAuCl4, MeOH, H2O, 80 °C, 6–72 h; (vi) TBAF, THF, rt, 12 h.

The Stille cross-coupling reaction was used for the synthesis of bipyridine and terpyridine C-nucleosides (Scheme 6). The reaction of 4 with tributyl(2-pyridyl)stannane catalyzed by PdCl2(PPh3)2 gave only compound 24a, as a product of chemoselective replacement of the bromine atom, in very good 82% yield even when we used 2 equiv. of stannane. The palladium catalyst is probably strongly coordinated to the bipyridine scaffold and any second reaction is prevented. In contrast, the Stille cross-coupling catalyzed by Pd(PPh3)4 cleanly afforded terpyridine C-nucleoside 25a, as a product of double substitution, in excellent 92% yield. Deprotection gave bi- and terpyridine C-nucleosides 24b and 25b which could be used in metalla-base pairs.14


Reagents and conditions: (i) 2 equiv. 2-pyridylSnBu3, PdCl2(PPh3)2, DMF, 100 °C, 12 h; (ii) 2 equiv. 2-pyridylSnBu3, Pd(PPh3)4, toluene, 110 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h.
Scheme 6 Reagents and conditions: (i) 2 equiv. 2-pyridylSnBu3, PdCl2(PPh3)2, DMF, 100 °C, 12 h; (ii) 2 equiv. 2-pyridylSnBu3, Pd(PPh3)4, toluene, 110 °C, 12 h; (iii) Et3N·3HF, THF, rt, 14 h.

Finally, we attempted to introduce a vinyl group by Fürstner's Fe-catalyzed cross-coupling reaction15 with vinylmagnesium bromide (Scheme 7). Unfortunately the cross-coupling did not proceed and, instead, the magnesiation of the bromopyridine occurred which, after hydrolytic work-up, gave chloropyridine 26a, as a product of debromination, in moderate 47% yield. Also this compound was deprotected to free nucleoside 26b.


Reagents and conditions: (i) vinylMgBr, Fe(acac)3, rt, 12 h; (ii) Et3N·3HF, THF, rt, 14 h.
Scheme 7 Reagents and conditions: (i) vinylMgBr, Fe(acac)3, rt, 12 h; (ii) Et3N·3HF, THF, rt, 14 h.

All the title free nucleosides were subjected to biological activity screening. The cytotoxic activity in vitro was studied on the following cell cultures: (i) human promyelocytic leukemia HL60 cells (ATCC CCL 240); (ii) human cervix carcinoma HeLa S3 cells (ATCC CCL 2.2); (iii) human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119), and (iv) hepatocellular carcinoma cells HepG2 (ATCC HB 8065). Cell viability was determined following a 3-day incubation using a metabolic 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) based method.16 The antiviral activity was tested against HCV genotype 1A, 1B and 2A replicons.17 None of the nucleosides showed any significant cytotoxicity or antiviral activity in these assays at concentrations up to 10 μM.

Conclusions

Systematic study of the chemoselectivity of cross-coupling reactions and nucleophilic substitutions of regioisomeric 2-bromo-6-chloro- and 6-bromo-2-chloropyridin-3-yl deoxyribo-nucleosides 7 and 4 was performed. The cross-couplings generally proceeded with good chemoselectivity at the position of the bromine but the choice of the starting compound depended on the separability of the mono-substituted products from the starting compound. On the other hand, nucleophilic substitution with NaSMe was unselective giving a separable mixture of both mono-substituted products, whereas the reactions with ammonia or NaOMe did not proceed or led to complex mixtures (at elevated temperature). The mono-substituted halopyridine C-nucleoside intermediates were used for another coupling or SN to give a small library of 2,6-disubstituted pyridin-3-yl C-deoxyribonucleosides. None of the title nucleosides exerted any antiviral or cytostatic activity in concentrations up to 10 μM. Some of the disubstituted pyridine nucleosides will be converted to triphosphates and further tested for polymerase incorporation in the quest for the extension of the genetic alphabet.2

Experimental

All cross-coupling reactions were carried out in evacuated flame-dried glassware with magnetic stirring under an argon atmosphere. THF, toluene, and hexanes were dried and distilled from sodium–benzophenone. Other reagents were purchased from commercial suppliers and used as received. NMR spectra were recorded on a 400 MHz spectrometer (1H at 400 MHz, 13C at 100.6 MHz), a 500 MHz spectrometer (1H at 500 and 13C MHz at 125.8), and/or a 600 MHz spectrometer (1H at 600 MHz, 13C at 151 MHz). The samples were measured in CDCl3 using TMS as an internal standard or in DMSO-d6 referenced to the residual solvent signal (1H NMR δ 2.50 ppm, 13C NMR 39.7 ppm). Chemical shifts are given in ppm (δ scale) and coupling constants (J) in hertz. Complete assignment of all NMR signals was performed using a combination of 2D-NMR (H,H-COSY, H,C-HSQC, and H,C-HMBC) experiments and configurations were established by two-dimensional ROESY spectra. High performance flash chromatography (HPFC) purifications were performed with Biotage SP1 apparatus on KP-Sil and KP-C18-HS columns. Cytostatic16 and anti-HCV17 activity screening was performed according to literature procedures.

General procedure for the deprotection of the TBDMS group

Et3N·3HF (320 μL, 1.95 mmol) was added to a solution of silylated C-nucleoside (0.4 mmol) in THF (2 mL), and the mixture was stirred at room temperature for 14 h. After the reaction was completed (TLC in hexanes–EtOAc 10[thin space (1/6-em)]:[thin space (1/6-em)]1), solvents were removed under reduced pressure, and the crude product was chromatographed on silica gel (20 g) eluted with a gradient of chloroform to 15% MeOH in chloroform to give free C-nucleosides.
1β-(6-Bromo-2-chloropyridin-3-yl)-1,2,3-trideoxy-3-oxo-D-ribofuranose (2). Freshly distilled CHCl3 (20 mL) was added to an argon-purged, flame-dried flask containing Pd(OAc)2 (390 mg, 1.74 mmol) and P(PhF5)3 (1.85 g, 3.47 mmol), and the mixture was stirred at room temperature for 30 min. This solution was then added via a syringe to a mixture of 6-bromo-2-chloro-3-iodopyridine (3.32 g, 10.42 mmol), glycal 1 (2.00 g, 8.68 mmol) and Ag2CO3 (3.58 g, 13.02 mmol) in CHCl3 (20 mL), and the reaction mixture was stirred at 70 °C for 10 h. The reaction mixture was then cooled and filtered on a pad of Celite and eluted with CHCl3. Solvents were removed under vacuum, the crude product was dissolved in THF (100 mL), Et3N·3HF (2 mL; 12.3 mmol) was added and the solution was stirred at rt for 15 min. The solvents were removed under vacuum, and the crude product was chromatographed on silica gel eluting with a gradient of chloroform to 1% MeOH in chloroform to give 2 (1.38 g, 52% for two steps) as a yellow oil. HRMS (ESI) for C10H9BrClNO3: [M − H] calculated, 303.9382; found, 303.9382. 1H NMR (500 MHz, CDCl3) 2.26 (dd, 1H, Jgem = 18.2 Hz, J2′a,1′ = 10.6 Hz, H-2′a); 3.18 (dd, 1H, Jgem = 18.2 Hz, J2′b,1′ = 6.2 Hz, H-2′b); 3.99–4.05 (m, 2H, H-5′); 4.11 (t, 1H, J4′,5′a = J4′,5′b = 3.4 Hz, H-4′); 5.43 (ddt, 1H, J1′,2′a = 10.6 Hz, J1′,2′b = 6.2 Hz, J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.52 (bd, 1H, J5,4 = 8.1 Hz, H-5); 7.97 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): 43.70 (CH2-2′); 61.51 (CH2-5′); 73.30 (CH-1′); 82.08 (CH-4′); 127.52 (CH-5); 134.64 (C-3); 137.72 (CH-4); 139.64 (C-6); 147.73 (C-2); 212.08 (C-3′). IR spectrum (KBr): 3436, 3095, 3068, 1760, 1574, 1546, 1426, 1221, 1033, 829, 736.
1β-(6-Bromo-2-chloropyridin-3-yl)-1,2-dideoxy-D-ribofuranose (3). NaBH(OAc)3 (1.53 g, 7.25 mmol) was added to a flame-dried flask containing a solution of the nucleoside 2 (1.48 g, 4.83 mmol) in a mixture of AcOH–CH3CN 1/10 (50 mL) at 0 °C under argon. After 5 min, all of the starting material was consumed and a solution of EtOH–H2O 1/1 (10 mL) was added to neutralize the solution. Then the solvents were evaporated in vacuum, and the crude product was chromatographed on silica gel in a gradient of chloroform to 5% MeOH in chloroform. Nucleoside 3 (1.27 g, 85%) was isolated as a white foam. HRMS (ESI) for C10H11BrClNO3: [M + H] calculated, 307.9684; found, 307.9684. 1H NMR (500 MHz, CD3OD) 1.78 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.47 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.68 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.71 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.5 Hz, H-5′b); 3.97 (td, 1H, J4′,5′a = J4′,5′b = 4.7 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.32 (bdtd, 1H, J3′,2′a = 5.9 Hz, J3′,4′ = J3′,2′b = 2.4 Hz, J3′,1′ = 0.5 Hz, H-3′); 5.32 (ddq, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.7 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.57 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 8.02 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 42.98 (CH2-2′); 63.66 (CH2-5′); 74.10 (CH-3′); 77.18 (CH-1′); 89.27 (CH-4′); 128.66 (CH-5); 138.16 (C-3); 139.46 (C-6); 139.96 (CH-4); 148.45 (C-2). IR spectrum (KBr): 3349, 3297, 3061, 1573, 1542, 1485, 1419, 1220, 1097, 1062, 1047, 823, 735.
1β-(6-Bromo-2-chloropyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (4). Imidazole (1.27 g, 18.6 mmol) and then TBDMSCl (4.49 mg, 29.8 mmol) were added to a flame-dried flask containing a solution of the nucleoside 3 (2.3 g, 7.45 mmol) in dry DMF (50 mL) at 0 °C under argon and the solution was allowed to warm to room temperature and was stirred for 14 h. The reaction mixture was then poured into a saturated solution of NaCl (100 mL) and extracted with EtOAc (3 × 30 mL). Collected organic fractions were washed with a saturated NaCl solution, dried over MgSO4, and the solvents were evaporated under vacuum. The crude product was chromatographed on silica gel in a gradient of hexanes to 5% EtOAc in hexanes to give the desired nucleoside 4 (3.1 g, 78%) as a colorless oil. HRMS (ESI) for C22H39BrClNO3Si2: [M + H] calculated, 536.1413; found, 536.1413. 1H NMR (500 MHz, CDCl3) 0.084, 0.086 and 0.094 (4 × s, 4 × 3H, CH3Si); 0.89 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.70 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.4 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.41 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.5 Hz, H-2′b); 3.71 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.6 Hz, H-5′a); 3.76 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.3 Hz, H-5′b); 3.97 (ddd, 1H, J4′,5′a = 4.6 Hz, J4′,5′b = 3.3 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.38 (dtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.6 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.33 (bddq, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 5.9 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.39 (dd, 1H, J5,4 = 8.0 Hz, J5,1′ = 0.6 Hz, H-5); 7.90 (dd, 1H, J4,5 = 8.0 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.49, −5.41, −4.76 and −4.62 (CH3Si); 17.98 and 18.29 ((CH3)3C); 25.75 and 25.87 ((CH3)3C); 42.30 (CH2-2′); 63.22 (CH2-5′); 73.65 (CH-3′); 75.84 (CH-1′); 87.95 (CH-4′); 127.01 (CH-5); 137.08 (C-3); 138.08 (CH-4), 138.38 (C-6); 147.48 (C-2). IR spectrum (CCl4): 3093, 3060, 2956, 2897, 1575, 1545, 1472, 1463, 1424, 1407, 1390, 1362, 1257, 1223, 1098, 1030, 1006, 939, 838, 671.
1β-(2-Bromo-6-chloropyridin-3-yl)-1,2,3-trideoxy-3-oxo-D-ribofuranose (5). Freshly distilled CHCl3 (18 mL) was added to an argon-purged, flame-dried flask containing Pd(OAc)2 (562 mg, 2.34 mmol) and P(PhF5)3 (2.49 g, 4.69 mmol), and the mixture was stirred at room temperature for 30 min. This solution was then added via a syringe to a mixture of 2-bromo-6-chloro-3-iodopyridine (4.48 g, 14.06 mmol), glycal 1 (2.70 g, 11.72 mmol) and Ag2CO3 (4.83 g, 17.58 mmol) in CHCl3 (18 mL), and the reaction mixture was stirred at 70 °C for 10 h. The reaction mixture was then cooled and filtered on a pad of Celite and eluted with CHCl3. Solvents were then removed in vacuum, the crude product was dissolved in THF (100 mL), Et3N·3HF (3 mL; 18.5 mmol) was added and the solution was stirred at rt for 15 min. The solvents were removed under vacuum, and the crude product was chromatographed on silica gel eluting with a gradient of chloroform to 1% MeOH in chloroform to give 5 (2.12 g, 59% for two steps) as a yellow foam. HRMS (ESI) for C10H9BrClNO3: [M − H] calculated, 303.9382; found, 303.9384. 1H NMR (500 MHz, CDCl3) 2.23 (dd, 1H, Jgem = 18.2 Hz, J2′a,1′ = 10.6 Hz, H-2′a); 3.21 (dd, 1H, Jgem = 18.2 Hz, J2′b,1′ = 6.2 Hz, H-2′b); 3.98–4.04 (m, 2H, H-5′); 4.11 (t, 1H, J4′,5′a = J4′,5′b = 3.3 Hz, H-4′); 5.41 (ddt, 1H, J1′,2′a = 10.6 Hz, J1′,2′b = 6.2 Hz, J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.37 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 8.03 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): 43.85 (CH2-2′); 61.44 (CH2-5′); 74.87 (CH-1′); 82.19 (CH-4′); 123.91 (CH-5); 136.72 (C-3); 137.85 (CH-4); 139.30 (C-2); 149.75 (C-6); 212.23 (C-3′). IR spectrum (KBr): 3428, 3095, 3071, 2924, 2854, 1760, 1630, 1575, 1546, 1460, 1429, 1224, 1057, 1032, 831, 735.
1β-(2-Bromo-6-chloropyridin-3-yl)-1,2-dideoxy-D-ribofuranose (6). NaBH(OAc)3 (2.9 g, 13.7 mmol) was added to a flame-dried flask containing a solution of the nucleoside 5 (2.8 g, 9.13 mmol) in a mixture of AcOH–CH3CN 1/10 (80 mL) at 0 °C under argon. After 5 min, all of the starting material was consumed and a solution of EtOH–H2O 1/1 (20 mL) was added to neutralize the solution. Then the solvents were evaporated in vacuum, and the crude product was chromatographed on silica gel in a gradient of chloroform to 5% MeOH in chloroform. Nucleoside 6 (2.45 g, 87%) was isolated as a white foam. HRMS (ESI) for C10H11BrClNO3: [M + H] calculated, 307.9684; found, 307.9683. 1H NMR (500 MHz, CD3OD) 1.76 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.51 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.1 Hz, H-2′b); 3.69 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.72 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.4 Hz, H-5′b); 3.97 (btd, 1H, J4′,5′a = J4′,5′b = 4.7 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.32 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 2.1 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.31 (ddq, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.8 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.44 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 8.07 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 43.18 (CH2-2′); 66.65 (CH2-5′); 74.09 (CH-3′); 78.88 (CH-1′); 89.32 (CH-4′); 124.95 (CH-5); 139.94 (C-2); 139.99 (CH-4); 140.20 (C-3); 149.82 (C-6). IR spectrum (KBr): 3376, 3267, 3098, 3059, 1574, 1548, 1486, 1470, 1267, 1070, 1044, 1017, 949, 932, 898.
1β-(2-Bromo-6-chloropyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (7). Imidazole (0.69 g, 10.18 mmol) and then TBDMSCl (2.45 mg, 16.3 mmol) were added to a flame-dried flask containing a solution of the nucleoside 6 (1.26 g, 4.07 mmol) in dry DMF (25 mL) at 0 °C under argon and the solution was allowed to warm to room temperature and was stirred for 14 h. The reaction mixture was then poured into a saturated solution of NaCl (100 mL) and extracted with EtOAc (3 × 50 mL). Collected organic fractions were washed with a saturated NaCl solution, dried over MgSO4, and the solvents were evaporated under vacuum. The crude product was chromatographed on silica gel in a gradient of hexanes to 3% EtOAc in hexanes to give the desired nucleoside 7 (2.01 g, 92%) as a colorless oil. HRMS (ESI) for C22H39BrClNO3Si2: [M + H] calculated, 536.1413; found, 536.1412. 1H NMR (500 MHz, CDCl3) 0.085, 0.089 and 0.10 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.68 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.4 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.45 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.6 Hz, H-2′b); 3.72 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.5 Hz, H-5′a); 3.77 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.3 Hz, H-5′b); 3.97 (ddd, 1H, J4′,5′a = 4.5 Hz, J4′,5′b = 3.3 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.38 (bdtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.7 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.31 (ddq, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 5.9 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.26 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 7.95 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.50, −5.42, −4.76 and −4.62 (CH3Si); 17.98 and 18.28 ((CH3)3C); 25.74 and 25.87 ((CH3)3C); 42.47 (CH2-2′); 63.21 (CH2-5′); 73.65 (CH-3′); 77.50 (CH-1′); 88.00 (CH-4′); 123.41 (CH-5); 138.08 (CH-4); 139.00 and 139.07 (C-2,3); 148.66 (C-6). IR spectrum (CCl4): 3093, 3059, 2956, 2897, 1577, 1545, 1472, 1463, 1406, 1390, 1362, 1278, 1258, 1097, 939, 891, 838.
1β-(2-Chloro-6-methylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (8a). Me3Al (1.5 mL, 1.5 mmol, 1.1 equiv., 1 M in heptane) was added to a flame-dried flask containing 4 (729 mg, 1.36 mmol) and Pd(PPh3)4 (161 mg, 0.14 mmol, 10 mol%) under argon. The mixture was stirred at 70 °C for 3 h, quenched by pouring into saturated NaH2PO4 (50 mL), and extracted with EtOAc (3 × 50 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 5% EtOAc in hexanes to give 8a (555 mg, 87%) as a colorless oil. HRMS (ESI) for C23H42ClNO3Si2: [M + H] calculated, 472.2465; found, 472.2465. 1H NMR (500 MHz, CDCl3) 0.083, 0.085, 0.087 and 0.093 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.70 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 9.5 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.40 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.5 Hz, H-2′b); 2.51 (s, 3H, CH3); 3.69 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 4.9 Hz, H-5′a); 3.77 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.96 (ddd, 1H, J4′,5′a = 4.9 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.38 (dtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.6 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.37 (bdd, 1H, J1′,2′a = 9.5 Hz, J1′,2′b = 5.8 Hz, H-1′); 7.06 (dm, 1H, J5,4 = 7.8 Hz, H-5); 7.88 (dd, 1H, J4,5 = 7.8 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.48, −5.42, −4.76 and −4.62 (CH3Si); 17.98 and 18.29 ((CH3)3C); 23.71 (CH3); 25.76 and 25.88 ((CH3)3C); 42.42 (CH2-2′); 63.33 (CH2-5′); 73.73 (CH-3′); 76.14 (CH-1′); 87.74 (CH-4′); 122.18 (CH-5); 134.16 (C-3); 136.10 (CH-4); 147.50 (C-2); 157.50 (C-6). IR spectrum (CCl4): 3068, 2956, 2898, 1597, 1569, 1555, 1471, 1462, 1435, 1407, 1389, 1376, 1362, 1257, 1220, 1097, 1031, 1006, 939, 838.
1β-(2-Chloro-6-methylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (8b). Compound 8b was prepared from 8a (225 mg, 0.93 mmol) by the general procedure to yield 8b (103 mg, 89%) as a yellow solid. HRMS (ESI) for C11H14ClNO3: [M + H] calculated, 244.0735; found, 244.0737. 1H NMR (500 MHz, CD3OD): 1.77 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.45 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.48 (s, 3H, CH3); 3.68 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.71 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.7 Hz, H-5′b); 3.97 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.32 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.36 (bdd, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.7 Hz, H-1′); 7.25 (dm, 1H, J5,4 = 7.8 Hz, H-5); 8.02 (dd, 1H, J4,5 = 7.8 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 23.24 (CH3); 43.20 (CH2-2′); 63.77 (CH2-5′); 74.16 (CH-3′); 77.44 (CH-1′); 89.12 (CH-4′); 123.97 (CH-5); 135.38 (C-3); 138.20 (CH-4); 148.33 (C-2); 159.17 (C-6). IR spectrum (KBr): 3356, 3230, 3066, 2986, 2919, 1599, 1554, 1463, 1439, 1379, 1171, 1061, 1040, 938.
1β-(2,6-Dimethylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (9a). Me3Al (1.4 mL, 1.4 mmol, 4.0 equiv., 1 M in heptane) was added to a flame-dried flask containing 4 (193 mg, 0.36 mmol) and Pd(PPh3)4 (42 mg, 0.036 mmol, 10 mol%) under argon. The mixture was stirred at 70 °C for 12 h, quenched by pouring into saturated NaH2PO4 (50 mL), and extracted with EtOAc (3 × 50 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 9% EtOAc in hexanes to give 9a (130 mg, 80%) as a colorless oil. HRMS (ESI) for C24H45NO3Si2: [M + H] calculated, 452.3011; found, 452.3010. 1H NMR (500 MHz, CDCl3): 0.08 and 0.09 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.73 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 5.5 Hz, H-2′a); 2.17 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.5 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.52 (s, 3H, CH3-2); 2.53 (s, 3H, CH3-6); 3.67 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 5.2 Hz, H-5′a); 3.78 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.6 Hz, H-5′b); 3.95 (ddd, 1H, J4′,5′a = 5.2 Hz, J4′,5′b = 3.6 Hz, J4′,3′ = 2.3 Hz, H-4′); 4.41 (bdtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.2 Hz, J3′,1′ = 0.5 Hz, H-3′); 5.28 (dd, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.4 Hz, H-1′); 6.99 (d, 1H, J5,4 = 8.0 Hz, H-5); 7.79 (d, 1H, J4,5 = 7.9 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.48, −5.40, −4.70 and −4.64 (CH3Si); 17.99 and 18.31 ((CH3)3C); 21.52 (CH3-2); 23.72 (CH3-6); 25.78 and 25.89 ((CH3)3C); 42.84 (CH2-2′); 63.49 (CH2-5′); 74.05 (CH-3′); 76.07 (CH-1′); 87.70 (CH-4′); 121.11 (CH-5); 133.37 (C-3); 134.11 (CH-4); 153.59 (C-2); 155.70 (C-6). IR spectrum (CCl4): 3068, 2956, 2930, 2897, 2858, 1596, 1578, 1471, 1463, 1450, 1406, 1390, 1372, 1362, 1290, 1257, 1090, 940, 838.
1β-(2,6-Dimethylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (9b). Compound 9b was prepared from 9a (152 mg, 0.34 mmol) by the general procedure to yield 9b (66 mg, 88%) as a yellow solid. HRMS (ESI) for C12H17NO3: [M + H] calculated, 224.1281; found, 224.1281. 1H NMR (500 MHz, CD3OD): 1.81 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.4 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.28 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.4 Hz, J2′b,3′ = 1.8 Hz, H-2′b); 2.47 (s, 3H, CH3-6); 2.49 (s, 3H, CH3-2); 3.67–3.71 (m, 2H, H-5′); 3.95 (td, 1H, J4′,5′a = J4′,5′b = 4.9 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.33 (bdt, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = J3′,2′b = 2.2 Hz, H-3′); 5.30 (dd, 1H, J1′,2′a = 10.4 Hz, J1′,2′b = 5.4 Hz, H-1′); 7.11 (bd, 1H, J5,4 = 8.0 Hz, H-5); 7.88 (d, 1H, J4,5 = 8.0 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 21.20 (CH3-2); 23.30 (CH3-6); 43.24 (CH2-2′); 63.84 (CH2-5′); 74.32 (CH-3′); 77.38 (CH-1′); 89.01 (CH-4′); 122.59 (CH-5); 134.68 (C-3); 135.88 (CH-4); 155.09 (C-2); 157.15 (C-6). IR spectrum (KBr): 3307, 1598, 1583, 1476, 1455, 1381, 1282, 1142, 1058, 1031, 976, 961.
1β-(2-Ethynyl-6-methylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (10a). DMF (3 mL) and TMSA (415 μL, 2.96 mmol) were added through a septum to an argon-purged vial containing 8a (280 mg, 0.59 mmol), Pd(PPh3)2Cl2 (42 mg, 0.06 mmol), CuI (1 mg, 0.005 mmol) and Et3N (827 μL, 5.93 mmol). The resulting mixture was stirred at 90 °C for 8 h. The reaction mixture was then cooled and filtered on a pad of Celite and eluted with CHCl3. Solvents were then removed in vacuum, the crude product was dissolved in methanolic ammonia (26%, 10 mL) and the solution was stirred at rt for 30 min. The solvents were removed under vacuum, and the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 8% EtOAc in hexanes to give 10a (153 mg, 56% for two steps) as a colorless oil. HRMS (ESI) for C25H43NO3Si2: [M + H] calculated, 462.2854; found, 462.2853. 1H NMR (500 MHz, DMSO-d6): 0.07, 0.08 and 0.09 (4 × s, 4 × 3H, CH3Si); 0.87 and 0.89 (2 × s, 2 × 9H, (CH3)3C)); 1.73 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.2 Hz, H-2′a); 2.22 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.5 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 2.43 (s, 3H, CH3-6); 3.61 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 5.9 Hz, H-5′a); 3.72 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 4.0 Hz, H-5′b); 3.85 (ddd, 1H, J4′,5′a = 5.9 Hz, J4′,5′b = 4.0 Hz, J4′,3′ = 1.9 Hz, H-4′); 4.37 (bdt, 1H, J3′,2′a = 5.2 Hz, J3′,4′ = J3′,2′b = 1.9 Hz, H-3′); 4.50 (s, 1H, CH[triple bond, length as m-dash]C-2); 5.37 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.5 Hz, H-1′); 7.28 (d, 1H, J5,4 = 8.1 Hz, H-5); 7.79 (bd, 1H, J4,5 = 8.1 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): −5.34, −5.26, −4.64 and −4.53 (CH3Si); 17.89 and 18.10 ((CH3)3C); 23.72 (CH3-6); 25.86 and 25.92 ((CH3)3C); 42.44 (CH2-2′); 63.38 (CH2-5′); 74.28 (CH-3′); 76.11 (CH-1′); 80.86 (CH[triple bond, length as m-dash]C-2); 84.26 (CH[triple bond, length as m-dash]C-2); 87.55 (CH-4′); 123.66 (CH-5); 133.72 (CH-4); 137.87 (C-3); 138.36 (C-2); 157.47 (C-6). IR spectrum (CCl4): 3310, 3062, 2956, 2929, 2897, 2858, 2523, 2803, 2113, 1585, 1566, 1472, 1463, 1445, 1406, 1389, 1361, 1370, 1275, 1258, 1177, 1098, 1087, 1006, 939, 838, 652, 632.
1β-(2-Ethynyl-6-methylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (10b). Compound 10b was prepared from 10a (97 mg, 0.11 mmol) by the general procedure to yield 10b (32 mg, 65%) as a yellow foam. HRMS (ESI) for C13H15NO3: [M + Na] calculated, 256.0944; found, 256.0944. 1H NMR (500 MHz, DMSO-d6): 1.66 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.20 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.6 Hz, J2′b,3′ = 1.7 Hz, H-2′b); 2.43 (s, 3H, CH3-6); 3.46 (dm, 1H, Jgem = 11.5 Hz, H-5′a); 3.51 (ddd, 1H, Jgem = 11.5 Hz, J5′b,OH = 5.6 Hz, J5′b,4′ = 4.8 Hz, H-5′b); 3.80 (btd, 1H, J4′,5′a = J4′,5′b = 5.0 Hz, J4′,3′ = 2.2 Hz, H-4′); 4.37 (m, 1H, H-3′); 4.50 (s, 1H, CH[triple bond, length as m-dash]C-2); 4.79 (t, 1H, JOH,5′a = JOH,5′b = 5.7 Hz, OH-5′); 5.12 (d, 1H, JOH,3′ = 3.8 Hz, OH-3′); 5.34 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.6 Hz, H-1′); 7.28 (d, 1H, J5,4 = 8.1 Hz, H-5); 7.86 (bd, 1H, J4,5 = 8.1 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): 23.72 (CH3-6); 42.77 (CH2-2′); 62.41 (CH2-5′); 72.58 (CH-3′); 76.05 (CH-1′); 81.10 (CH[triple bond, length as m-dash]C-2); 84.10 (CH[triple bond, length as m-dash]C-2); 88.00 (CH-4′); 123.75 (CH-5); 134.14 (CH-4); 138.33 and 138.44 (C-2,3); 157.27 (C-6). IR spectrum (KBr): 3366, 3064, 2980, 2929, 2106, 2095, 1590, 1567, 1449, 1378, 1346, 1332, 1288, 1179, 1161, 1118, 1083, 1062, 1050, 969, 938, 655, 639.
1β-(2-Amino-6-methylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (11a). LiN(SiMe3)2 (1.6 mL, 1.6 mmol, 3 equiv. 1.0 M solution in THF) was added to a flame-dried and argon-purged flask containing 8a (255 mg, 0.54 mmol), Ph3SiNH2 (297 mg, 1.1 mmol), Pd2(dba)3 (28 mg, 0.027 mmol, 5 mol%), and (biphenyl-2-yl)dicyclohexylphosphane (38 mg, 0.11 mmol, 20 mol%), and the mixture was stirred at 50 °C for 3 h. After cooling to room temperature, the reaction mixture was diluted with Et2O (30 mL), and washed with 2 M HCl (10 mL) and 1 M NaOH (15 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 17% EtOAc in hexanes to give 11a (167 mg, 68%) as a colorless oil. HRMS (ESI) for C23H44N2O3Si2: [M + H] calculated, 453.2963; found, 453.2963. 1H NMR (500 MHz, CDCl3) 0.07, 0.079, 0.081 and 0.09 (4 × s, 4 × 3H, CH3Si); 0.90 (2 × s, 2 × 9H, ((CH3)3C)); 1.86 (ddd, 1H, Jgem = 12.8 Hz, J2′a,1′ = 5.6 Hz, J2′a,3′ = 1.6 Hz, H-2′a); 2.35 (s, 3H, CH3); 2.38 (ddd, 1H, Jgem = 12.8 Hz, J2′b,1′ = 10.8 Hz, J2′b,3′ = 6.5 Hz, H-2′b); 3.77 (dd, 1H, Jgem = 11.1 Hz, J5′a,4′ = 2.4 Hz, H-5′a); 3.83 (dd, 1H, Jgem = 11.1 Hz, J5′b,4′ = 3.0 Hz, H-5′b); 3.90 (bq, 1H, J4′,5′a = J4′,5′b = J4′,3′ = 2.7 Hz, H-4′); 4.45 (bddd, 1H, J3′,2′b = 6.5 Hz, J3′,4′ = 2.9 Hz, J3′,2′a = 1.6 Hz, H-3′); 5.01 (dd, 1H, J1′,2′b = 10.8 Hz, J1′,2′a = 5.6 Hz, H-1′); 5.31 (bs, 2H, NH2); 6.42 (bd, 1H, J5,4 = 7.4 Hz, H-5); 7.19 (d, 1H, J4,5 = 7.4 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.57, −5.51, −4.72 and −4.58 (CH3Si); 18.02 and 18.43 ((CH3)3C); 23.73 (CH3); 25.80 and 25.88 ((CH3)3C); 39.94 (CH2-2′); 62.93 (CH2-5′); 73.55 (CH-3′); 80.27 (CH-1′); 88.23 (CH-4′); 112.11 (CH-5); 114.81 (C-3); 137.04 (CH-4); 155.94 (C-6); 156.38 (C-2). IR spectrum (CCl4): 3488, 3372, 3062, 2956, 2930, 2896, 2585, 1609, 1595, 1582, 1472, 1463, 1445, 1408, 1390, 1374, 1362, 1258, 1097, 1006, 938, 837.
1β-(2-Amino-6-methylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (11b). Compound 11b was prepared from 11a (97 mg, 0.11 mmol) by the general procedure to yield 11b (85 mg, 82%) as a yellow solid. HRMS (ESI) for C11H16N2O3: [M + H] calculated, 225.1234; found, 225.1234. 1H NMR (500 MHz, DMSO-d6): 1.88 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 5.6 Hz, J2′a,3′ = 1.8 Hz, H-2′a); 2.03 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 10.5 Hz, J2′b,3′ = 6.3 Hz, H-2′b); 2.21 (s, 3H, CH3); 3.50 (ddd, 1H, Jgem = 11.5 Hz, J5′a,OH = 5.4 Hz, J5′a,4′ = 3.9 Hz, H-5′a); 3.54 (ddd, 1H, Jgem = 11.5 Hz, J5′b,OH = 4.9 Hz, J5′b,4′ = 3.6 Hz, H-5′b); 3.73 (td, 1H, J4′,5′a = J4′,5′b = 3.8 Hz, J4′,3′ = 2.8 Hz, H-4′); 4.20 (m, 1H, H-3′); 4.91 (dd, 1H, J1′,2′b = 10.5 Hz, J1′,2′a = 5.6 Hz, H-1′); 4.93 (t, 1H, JOH,5′a = JOH,5′b = 5.2 Hz, OH-5′); 5.02 (d, 1H, JOH,3′ = 4.1 Hz, OH-3′); 5.76 (bs, 2H, NH2); 6.34 (bdd, 1H, J5,4 = 7.4 Hz, J5,LR = 0.6 Hz, H-5); 7.26 (bd, 1H, J4,5 = 7.4 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): 23.68 (CH3); 39.76 (CH2-2′); 61.72 (CH2-5′); 72.13 (CH-3′); 78.13 (CH-1′); 87.82 (CH-4′); 111.08 (CH-5); 115.60 (C-3); 135.83 (CH-4); 155.00 (C-6); 156.60 (C-2). IR spectrum (KBr): 3393, 3317, 3200, 3149, 3086, 2951, 2919, 2773, 1626, 1595, 1587, 1444, 1379, 1347, 1328, 1281, 1185, 1100, 1081, 1042, 977, 938, 831.
1β-(2-Methoxy-6-methylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (12). MeONa (605 mg, 11 mmol) was added to a solution of the nucleoside 8b (53 mg, 0.22 mmol) in methanol (10 mL) and the mixture was stirred for 10 days at 120 °C. Then the solvents were evaporated under vacuum. The crude product was chromatographed on silica gel in a gradient of chloroform to 6% MeOH in chloroform to give 12 (40 mg, 77%) as a white solid. HRMS (ESI) for C12H17NO4: [M + Na] calculated, 262.1050; found, 262.1050. 1H NMR (500 MHz, CD3OD): 1.77 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.31 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.6 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 2.40 (s, 3H, CH3-6); 3.64 (dd, 1H, Jgem = 11.6 Hz, J5′a,4′ = 5.1 Hz, H-5′a); 3.66 (dd, 1H, Jgem = 11.6 Hz, J5′b,4′ = 5.2 Hz, H-5′b); 3.91 (s, 3H, CH3O); 3.92 (td, 1H, J4′,5′a = J4′,5′b = 5.2 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.27 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 1.9 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.26 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.6 Hz, H-1′); 6.77 (dm, 1H, J5,4 = 7.4 Hz, H-5); 7.71 (dd, 1H, J4,5 = 7.4 Hz, J4,1′ = 0.9 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 23.69 (CH3-6); 42.93 (CH2-2′); 53.54 (CH3O-2); 64.01 (CH2-5′); 74.32 (CH-3′); 76.08 (CH-1′); 88.69 (CH-4′); 116.83 (CH-5); 122.92 (C-3); 136.38 (CH-4); 155.78 (C-6); 161.26 (C-2). IR spectrum (KBr): 3386, 3079, 2988, 2951, 2923, 2853, 1603, 1588, 1461, 1444, 1383, 1327, 1246, 1192, 1116, 1089, 1082, 1049, 1031, 966, 942, 821.
1β-(6-Chloro-2-phenylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (13a). K2CO3 (86 mg, 0.62 mmol), Pd(PPh3)4 (24 mg, 0.02 mmol, 5 mol%), PhB(OH)2 (45 mg, 0.37 mmol, 0.9 equiv.) and starting nucleoside 7 (222 mg, 0.41 mmol) were dissolved in toluene (2 mL) under argon, and the mixture was stirred at 60 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 1% EtOAc in hexanes to give 13a (140 mg, 63%) as a colorless oil. HRMS (ESI) for C28H44ClNO3Si2: [M + H] calculated, 534.2621; found, 534.2621. 1H NMR (500 MHz, CDCl3): −0.01, 0.02, 0.09 and 0.10 (4 × s, 4 × 3H, CH3Si); 0.82 and 0.92 (2 × s, 2 × 9H, ((CH3)3C)); 1.81 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.4 Hz, H-2′a); 1.96 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.3 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 3.67 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.8 Hz, H-5′a); 3.74 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.3 Hz, H-5′b); 3.85 (ddd, 1H, J4′,5′a = 4.8 Hz, J4′,5′b = 3.3 Hz, J4′,3′ = 2.1 Hz, H-4′); 4.36 (dtd, 1H, J3′,2′a = 5.5 Hz, J3′,4′ = J3′,2′b = 2.0 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.22 (bddq, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.3 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.30 (dd, 1H, J5,4 = 8.3 Hz, J5,1′ = 0.7 Hz, H-5); 7.38–7.46 (m, 5H, H-o,m,p-Ph); 8.05 (dd, 1H, J4,5 = 8.3 Hz, J4,1′ = 0.6 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.51, −5.39, −4.80 and −4.76 (CH3Si); 17.86 and 18.31 ((CH3)3C); 25.67 and 25.89 ((CH3)3C); 44.62 (CH2-2′); 63.53 (CH2-5′); 74.20 (CH-3′); 75.74 (CH-1′); 87.91 (CH-4′); 123.01 (CH-5); 128.23 and 128.95 (CH-o,m-Ph); 128.58 (CH-p-Ph); 134.90 (C-3); 137.99 (CH-4); 138.33 (C-i-Ph); 149.33 (C-6); 157.84 (C-2). IR spectrum (CCl4): 3087, 3063, 3034, 2956, 2989, 1575, 1558, 1496, 1471, 1463, 1408, 1388, 1361, 1257, 1088, 1027, 1006, 939, 838.
1β-(6-Chloro-2-phenylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (13b). Compound 13b was prepared from 13a (160 mg, 0.30 mmol) by the general procedure to yield 13b (84 mg, 91%) as a white solid. HRMS (ESI) for C22H21NO3: [M + H] calculated, 348.1594; found, 348.1593. 1H NMR (500 MHz, CD3OD): 2.01 (ddd, 1H, Jgem = 13.2 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 5.9 Hz, H-2′a); 2.06 (ddd, 1H, Jgem = 13.2 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.70 (m, 1H, H-5′a); 3.72 (m, 1H, H-5′b); 3.85 (btd, 1H, J4′,5′a = J4′,5′b = 4.7 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.31 (bdddd, 1H, J3′,2′a = 5.9 Hz, J3′,4′ = 2.8 Hz, J3′,2′b = 1.9 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.24 (bddq, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.8 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.41 (m, 1H, H-p-Ph-6); 7.44–7.49 (m, 3H, H-m-Ph-6, H-p-Ph-2); 7.50 (m, 2H, H-m-Ph-2); 7.55 (m, 2H, H-o-Ph-2); 7.85 (dd, 1H, J5,4 = 8.3 Hz, J5,1′ = 0.6 Hz, H-5); 8.01 (m, 2H, H-o-Ph-6); 8.22 (dd, 1H, J4,5 = 8.3 Hz, J4,1′ = 0.5 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 44.89 (CH2-2′); 63.86 (CH2-5′); 74.42 (CH-3′); 77.59 (CH-1′); 89.06 (CH-4′); 121.00 (CH-5); 128.22 (CH-o-Ph-6); 129.33 (CH-m-Ph-2); 129.43 (CH-p-Ph-2); 129.72 (CH-m-Ph-6); 130.10 (CH-p-Ph-6); 130.32 (CH-o-Ph-2); 135.29 (C-3); 137.71 (CH-4); 140.31 (C-i-Ph-6); 141.23 (C-i-Ph-2); 157.47 (C-6); 159.02 (C-2). IR spectrum (KBr): 3412, 3084, 3061, 3031, 1574, 1559, 1495, 1449, 1277, 1146, 1083, 1075, 1024, 1000, 940, 831.
1β-(2,6-Diphenylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (14a). K2CO3 (129 mg, 0.93 mmol), Pd(PPh3)4 (21 mg, 0.0185 mmol, 5 mol%), PhB(OH)2 (135 mg, 1.11 mmol, 3 equiv.) and starting nucleoside 7 (200 mg, 0.37 mmol) were dissolved in toluene (2 mL) under argon, and the mixture was stirred at 100 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 1% EtOAc in hexanes to give 14a (205 mg, 95%) as a colorless oil. HRMS (ESI) for C34H49NO3Si2: [M + H] calculated, 576.3324; found, 576.3323. 1H NMR (500 MHz, CDCl3): 0.04, 0.06, 0.12 and 0.14 (4 × s, 4 × 3H, CH3Si); 0.86 and 0.96 (2 × s, 2 × 9H, ((CH3)3C)); 1.91 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.4 Hz, H-2′a); 2.03 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.3 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 3.71 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 5.1 Hz, H-5′a); 3.80 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.90 (ddd, 1H, J4′,5′a = 5.1 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.2 Hz, H-4′); 4.42 (bdt, 1H, J3′,2′a = 5.4 Hz, J3′,4′ = J3′,2′b = 2.1 Hz, H-3′); 5.33 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.3 Hz, H-1′); 7.38–7.45 (m, 2H, H-p-Ph-2,6); 7.44–7.49 (m, 4H, H-m-Ph-2,6); 7.57 (m, 2H, H-o-Ph-2); 7.74 (dd, 1H, J5,4 = 8.2 Hz, J5,1′ = 0.6 Hz, H-5); 8.08 (m, 2H, H-o-Ph-6); 8.14 (bd, 1H, J4,5 = 8.2 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.47, −5.36, −4.78 and −4.74 (CH3Si); 17.88 and 18.33 ((CH3)3C); 25.70 and 25.92 ((CH3)3C); 44.53 (CH2-2′); 63.61 (CH2-5′); 74.28 (CH-3′); 76.16 (CH-1′); 87.78 (CH-4′); 119.21 (CH-5); 127.07 (CH-o-Ph-6); 128.06 (CH-m-Ph-2); 128.11 (CH-p-Ph-2); 128.59 (CH-m-Ph-6); 128.80 (CH-p-Ph-6); 129.22 (CH-o-Ph-2); 134.17 (C-3); 135.75 (CH-4); 139.16 (C-i-Ph-6); 139.94 (C-i-Ph-2); 155.58 (C-6); 157.17 (C-2). IR spectrum (CCl4): 3110, 3086, 3064, 3034, 2956, 2897, 1602, 1588, 1576, 1563, 1495, 1472, 1463, 1442, 1406, 1389, 1361, 1280, 1258, 1096, 1030, 939, 838.
1β-(2,6-Diphenylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (14b). Compound 14b was prepared from 14a (205 mg, 0.36 mmol) by the general procedure to yield 14b (100 mg, 81%) as a white solid. HRMS (ESI) for C22H21NO3: [M + H] calculated, 348.1594; found, 348.1593. 1H NMR (500 MHz, CD3OD): 2.01 (ddd, 1H, Jgem = 13.2 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 5.9 Hz, H-2′a); 2.06 (ddd, 1H, Jgem = 13.2 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.70 (m, 1H, H-5′a); 3.72 (m, 1H, H-5′b); 3.85 (btd, 1H, J4′,5′a = J4′,5′b = 4.7 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.31 (bdddd, 1H, J3′,2′a = 5.9 Hz, J3′,4′ = 2.8 Hz, J3′,2′b = 1.9 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.24 (bddq, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.8 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.41 (m, 1H, H-p-Ph-6); 7.44–7.49 (m, 3H, H-m-Ph-6, H-p-Ph-2); 7.50 (m, 2H, H-m-Ph-2); 7.55 (m, 2H, H-o-Ph-2); 7.85 (dd, 1H, J5,4 = 8.3 Hz, J5,1′ = 0.6 Hz, H-5); 8.01 (m, 2H, H-o-Ph-6); 8.22 (dd, 1H, J4,5 = 8.3 Hz, J4,1′ = 0.5 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 44.89 (CH2-2′); 63.86 (CH2-5′); 74.42 (CH-3′); 77.59 (CH-1′); 89.06 (CH-4′); 121.00 (CH-5); 128.22 (CH-o-Ph-6); 129.33 (CH-m-Ph-2); 129.43 (CH-p-Ph-2); 129.72 (CH-m-Ph-6); 130.10 (CH-p-Ph-6); 130.32 (CH-o-Ph-2); 135.29 (C-3); 137.71 (CH-4); 140.31 (C-i-Ph-6); 141.23 (C-i-Ph-2); 157.47 (C-6); 159.02 (C-2). IR spectrum (KBr): 3412, 3110, 3083, 3059, 3031, 1602, 1587, 1574, 1562, 1493, 1282, 1075, 1046, 1028, 941.
1β-(6-Amino-2-phenylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (15a). LiN(SiMe3)2 (1.5 mL, 1.5 mmol, 3 equiv. 1.0 M solution in THF) was added to a flame-dried and argon-purged flask containing 14a (262 mg, 0.49 mmol), Pd2(dba)3 (45 mg, 0.049 mmol, 10 mol%), and (biphenyl-2-yl)dicyclohexylphosphane (35 mg, 0.098 mmol, 20 mol%), and the mixture was stirred at 60 °C for 12 h. After cooling to room temperature, the reaction mixture was diluted with Et2O (30 mL), washed with 2 M HCl (10 mL) and 1 M NaOH (15 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 20% EtOAc in hexanes to give 15a (230 mg, 91%) as a colorless oil. HRMS (ESI) for C28H46N2O3Si2: [M + H] calculated, 515.3120; found, 515.3118. 1H NMR (500 MHz, CDCl3): 0.01, 0.02, 0.085 and 0.093 (4 × s, 4 × 3H, CH3Si); 0.82 and 0.93 (2 × s, 2 × 9H, ((CH3)3C)); 1.86 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.4 Hz, H-2′a); 1.93 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.4 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 3.64 (dd, 1H, Jgem = 10.7 Hz, J5′a,4′ = 5.2 Hz, H-5′a); 3.74 (dd, 1H, Jgem = 10.7 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.79 (ddd, 1H, J4′,5′a = 5.2 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.1 Hz, H-4′); 4.36 (dt, 1H, J3′,2′a = 5.4 Hz, J3′,4′ = J3′,2′b = 2.0 Hz, H-3′); 5.10 (dd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.3 Hz, H-1′); 6.51 (bd, 1H, J5,4 = 8.5 Hz, H-5); 7.36 (m, 1H, H-p-Ph); 7.39 (m, 2H, H-m-Ph); 7.41 (m, 2H, H-o-Ph); 7.77 (d, 1H, J4,5 = 8.5 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.50, −5.39, −4.78 and −4.75 (CH3Si); 17.86 and 18.31 ((CH3)3C); 25.68 and 25.91 ((CH3)3C); 44.29 (CH2-2′); 63.68 (CH2-5′); 74.29 (CH-3′); 76.02 (CH-1′); 87.45 (CH-4′); 108.00 (CH-5); 124.93 (C-3); 127.90 (CH-p-Ph); 128.03 (CH-m-Ph); 128.84 (CH-o-Ph); 137.26 (CH-4); 139.65 (C-i-Ph); 155.80 (C-2); 156.81 (C-6). IR spectrum (CCl4): 2506, 3407, 3301, 3169, 3084, 3063, 3030, 2956, 2897, 1631, 1610, 1572, 1496, 1473, 1464, 1444, 1410, 1389, 1361, 1290, 1256, 1097, 1029, 939, 838.
1β-(6-Amino-2-phenylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (15b). Compound 15b was prepared from 15a (200 mg, 0.39 mmol) by the general procedure to yield 15b (70 mg, 67%) as a yellow solid. HRMS (ESI) for C16H18N2O3: [M + H] calculated, 287.1390; found, 287.1390. 1H NMR (500 MHz, DMSO-d6): 1.84 (ddd, 1H, Jgem = 12.8 Hz, J2′a,1′ = 5.9 Hz, J2′a,3′ = 2.1 Hz, H-2′a); 1.88 (ddd, 1H, Jgem = 12.8 Hz, J2′b,1′ = 10.1 Hz, J2′b,3′ = 5.4 Hz, H-2′b); 3.40–3.49 (m, 2H, H-5′); 3.60 (bddd, 1H, J4′,5′a = 5.3 Hz, J4′,5′b = 4.8 Hz, J4′,3′ = 2.2 Hz, H-4′); 4.15 (m, 1H, H-3′); 4.71 (bt, 1H, JOH,5′a = JOH,5′b = 5.6 Hz, OH-5′); 4.85 (dd, 1H, J1′,2′b = 10.1 Hz, J1′,2′a = 5.8 Hz, H-1′); 4.85 (d, 1H, JOH,3′ = 3.8 Hz, OH-3′); 6.13 (bs, 2H, NH2); 6.54 (bd, 1H, J5,4 = 8.6 Hz, H-5); 7.38–7.46 (m, 5H, H-o,m,p-Ph); 7.67 (bd, 1H, J4,5 = 8.6 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): 43.08 (CH2-2′); 62.61 (CH2-5′); 72.71 (CH-3′); 75.47 (CH-1′); 87.54 (CH-4′); 108.25 (CH-5); 122.25 (C-3); 128.02 (CH-m,p-Ph); 129.13 (CH-o-Ph); 137.98 (CH-4); 139.50 (C-i-Ph); 154.35 (C-2); 157.89 (C-6). IR spectrum (KBr): 3358, 3217, 3059, 1621, 1600, 1571, 1496, 1444, 1217, 1181, 1158, 1074, 1047, 830.
1β-(6-Methyl-2-phenylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (16a). Me3Al (0.92 mL, 0.92 mmol, 3.0 equiv., 1 M in heptane) was added to a flame-dried flask containing a solution of 14a (164 mg, 0.31 mmol) and Pd(PPh3)4 (36 mg, 0.031 mmol, 10 mol%) in THF (5 mL). The mixture was stirred at 70 °C for 12 h, quenched by pouring into saturated NaH2PO4 (50 mL), and extracted with EtOAc (3 × 50 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 6% EtOAc in hexanes to give 16a (144 mg, 91%) as a colorless oil. HRMS (ESI) for C29H47NO3Si2: [M + H] calculated, 514.3167; found, 514.3166. 1H NMR (500 MHz, CDCl3): −0.01, 0.02, 0.08 and 0.10 (4 × s, 4 × 3H, CH3Si); 0.82 and 0.92 (2 × s, 2 × 9H, ((CH3)3C)); 1.81 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.4 Hz, H-2′a); 1.93 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.3 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 2.62 (s, 3H, CH3-6); 3.66 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 5.1 Hz, H-5′a); 3.75 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.83 (ddd, 1H, J4′,5′a = 5.1 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.2 Hz, H-4′); 4.36 (dtd, 1H, J3′,2′a = 5.4 Hz, J3′,4′ = J3′,2′b = 2.0 Hz, J3′,1′ = 0.5 Hz, H-3′); 5.18 (dd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.3 Hz, H-1′); 7.16 (d, 1H, J5,4 = 8.1 Hz, H-5); 7.38 (m, 1H, H-p-Ph); 7.40–7.44 (m, 4H, H-o,m-Ph); 7.97 (d, 1H, J4,5 = 8.1 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.49, −5.39, −4.81 and −4.76 (CH3Si); 17.85 and 18.31 ((CH3)3C); 24.06 (CH3-6); 25.68 and 25.90 ((CH3)3C); 44.49 (CH2-2′); 63.59 (CH2-5′); 74.23 (CH-3′); 76.06 (CH-1′); 87.72 (CH-4′); 122.38 (CH-5); 128.14 (CH-p-Ph); 128.18 (CH-m-Ph); 128.97 (CH-o-Ph); 132.93 (C-3); 135.53 (CH-4); 139.32 (C-i-Ph); 156.52 (C-2,6). IR spectrum (CCl4): 3110, 3083, 3061, 3029, 2956, 2930, 2897, 2858, 1593, 1569, 1495, 1471, 1463, 1406, 1389, 1371, 1361, 1289, 1257, 1095, 1030, 1006, 939, 838.
1β-(6-Methyl-2-phenylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (16b). Compound 16b was prepared from 16a (144 mg, 0.28 mmol) by the general procedure to yield 16b (68 mg, 85%) as a white solid. HRMS (ESI) for C17H19NO3: [M + H] calculated, 286.1438; found, 286.1438. 1H NMR (500 MHz, CD3OD): 1.93 (ddd, 1H, Jgem = 13.2 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.9 Hz, H-2′a); 1.99 (ddd, 1H, Jgem = 13.2 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 2.54 (s, 3H, CH3-6); 3.64–3.71 (m, 2H, H-5′); 3.80 (bddd, 1H, J4′,5′a = 5.0 Hz, J4′,5′b = 4.5 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.27 (bdddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 1.9 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.10 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.8 Hz, H-1′); 7.32 (bd, 1H, J5,4 = 8.1 Hz, H-5); 7.42 (m, 2H, H-o-Ph); 7.43–7.51 (m, 3H, H-m,p-Ph); 8.09 (d, 1H, J4,5 = 8.1 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 23.38 (CH3-6); 44.85 (CH2-2′); 63.82 (CH2-5′); 74.36 (CH-3′); 77.47 (CH-1′); 89.02 (CH-4′); 124.14 (CH-5); 129.40 (CH-m-Ph); 129.52 (CH-p-Ph); 130.11 (CH-o-Ph); 134.25 (C-3); 137.65 (CH-4); 140.70 (C-i-Ph); 158.02 (C-6); 158.29 (C-2). IR spectrum (KBr): 1595, 1573, 1496, 1476, 1447, 1380, 1281, 1146, 1086, 1040, 961.
1β-[2,6-Bis(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (17). MeSNa (59 mg, 0.84 mmol) was added to a solution of the nucleoside 4 (45 mg, 0.084 mmol) in DMF (2 mL) and the mixture was stirred for 12 h at 80 °C. Then the solvents were evaporated under vacuum. The crude product was chromatographed on silica gel in a gradient of chloroform to 7% MeOH in chloroform to give 17 (19 mg, 79%) as a pale yellow solid. HRMS (ESI) for C12H17NO3S2: [M + Na] calculated, 310.0542; found, 310.0542. 1H NMR (500 MHz, CD3OD): 1.75 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.36 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.6 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.57 (s, 3H, CH3S-6); 2.59 (s, 3H, CH3S-2); 3.67–3.70 (m, 2H, H-5′); 3.92 (td, 1H, J4′,5′a = J4′,5′b = 4.9 Hz, J4′,3′ = 2.8 Hz, H-4′); 4.30 (dddd, 1H, J3′,2′a = 6.1 Hz, J3′,4′ = 2.8 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.27 (ddq, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.6 Hz, J1′,4 = J1′,5 = J1′,3′ = 0.7 Hz, H-1′); 6.93 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 7.65 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 11.46 and 11.56 (CH3S-2,6); 41.24 (CH2-2′); 62.13 (CH2-5′); 72.62 (CH-3′); 75.06 (CH-1′); 87.16 (CH-4′); 115.88 (CH-5); 130.16 (C-3); 132.32 (CH-4); 155.15 (C-2); 157.48 (C-6). IR spectrum (KBr): 3411, 2989, 2924, 1565, 1543, 1430, 1418, 1335, 1308, 1217, 1049, 962, 840, 778.
1β-[2-Chloro-6-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (18a). MeSNa (48 mg, 0.69 mmol, 1.2 equiv.) was added to a solution of the nucleoside 4 (310 mg, 0.58 mmol) in DMF (5 mL) and the mixture was stirred for 12 h at rt. Then the solvents were evaporated under vacuum. The crude product was purified using high performance flash chromatography with a gradient of hexanes to 1% EtOAc in hexanes to give products 18a (141 mg, 48%) as a white solid and 19a (136 mg, 43%) as a white solid. Compound 18a: HRMS (ESI) for C23H42ClNO3SSi2: [M + H] calculated, 504.2185; found, 504.2183. 1H NMR (500 MHz, CDCl3) 0.082, 0.084 and 0.09 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.70 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 9.5 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.37 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.5 Hz, H-2′b); 2.56 (s, 3H, CH3S-6); 3.69 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 4.8 Hz, H-5′a); 3.76 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.95 (ddd, 1H, J4′,5′a = 5.7 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.38 (dtd, 1H, J3′,2′a = 5.7 Hz, J3′,4′ = J3′,2′b = 2.5 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.35 (ddq, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 5.8 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz,H-1′); 7.08 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.6 Hz, H-5); 7.80 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.48, −5.40, −4.75 and −4.62 (CH3Si); 13.51 (CH3S-6); 17.99 and 18.30 ((CH3)3C); 25.77 and 25.88 ((CH3)3C); 42.47 (CH2-2′); 63.32 (CH2-5′); 73.72 (CH-3′); 76.01 (CH-1′); 87.76 (CH-4′); 120.24 (CH-5); 132.38 (C-3); 135.72 (CH-4); 147.97 (C-2); 158.71 (C-6). IR spectrum (CCl4): 3078, 3058, 2956, 2897, 1587, 1537, 1472, 1439, 1408, 1390, 1373, 1361, 1318, 1258, 1096, 939, 838.
1β-[6-Bromo-2-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (19a). HRMS (ESI) for C23H42BrNO3SSi2: [M + H] calculated, 548.1680; found, 548.1675. 1H NMR (500 MHz, CDCl3) 0.09, 0.098, 0.100 and 0.11 (4 × s, 4 × 3H, CH3Si); 0.91 and 0.93 (2 × s, 2 × 9H, ((CH3)3C)); 1.68 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.4 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.38 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.6 Hz, H-2′b); 2.59 (s, 3H, CH3S-2); 3.70 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.9 Hz, H-5′a); 3.78 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.95 (ddd, 1H, J4′,5′a = 4.9 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.39 (dtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.7 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.27 (ddq, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 5.9 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.15 (dd, 1H, J5,4 = 8.0 Hz, J5,1′ = 0.6 Hz, H-5); 7.67 (dd, 1H, J4,5 = 8.0 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.48, −5.41, −4.76 and −4.61 (CH3Si); 13.35 (CH3S-2); 17.99 and 18.30 ((CH3)3C); 25.78 and 25.89 ((CH3)3C); 41.82 (CH2-2′); 63.24 (CH2-5′); 73.73 (CH-3′); 75.03 (CH-1′); 87.57 (CH-4′); 122.85 (CH-5); 134.71 (CH-4); 135.45 (C-3); 139.46 (C-6); 157.09 (C-2). IR spectrum (CCl4): 3057, 2956, 2897, 1571, 1543, 1472, 1463, 1414, 1390, 1374, 1310, 1288, 1216, 1097, 1030, 961, 939, 838.
1β-[2-Chloro-6-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (18b). Compound 18b was prepared from 18a (141 mg, 0.28 mmol) by the general procedure to yield 18b (66 mg, 86%) as a white solid. HRMS (ESI) for C11H14ClNO3S: [M + Na] calculated, 298.0275; found, 298.0277. 1H NMR (500 MHz, CD3OD): 1.77 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.42 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.6 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 2.53 (s, 3H, CH3S-6); 3.68 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.70 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.6 Hz, H-5′b); 3.95 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.31 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 1.9 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.34 (ddq, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.6 Hz, J1′,4 = J1′,5 = J1′,3′ = 0.7 Hz, H-1′); 7.21 (dd, 1H, J5,4 = 8.2 Hz, J5,1′ = 0.6 Hz, H-5); 7.90 (dd, 1H, J4,5 = 8.2 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 13.48 (CH3S-6); 43.23 (CH2-2′); 63.77 (CH2-5′); 74.19 (CH-3′); 77.38 (CH-1′); 89.11 (CH-4′); 121.34 (CH-5); 133.08 (C-3); 137.46 (CH-4); 149.04 (C-2); 160.92 (C-6). IR spectrum (KBr): 3333, 3284, 1048, 1585, 1576, 1543, 1425, 1317, 1219, 957, 832.
1β-[6-Bromo-2-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (19b). Compound 19b was prepared from 19a (136 mg, 0.25 mmol) by the general procedure to yield 19b (62 mg, 78%) as a white solid. HRMS (ESI) for C11H14BrNO3S: [M + Na] calculated, 341.9770; found, 341.9771. 1H NMR (500 MHz, CD3OD): 1.73 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.42 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.55 (s, 3H, CH3S-2); 3.67 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.70 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.6 Hz, H-5′b); 3.93 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.8 Hz, H-4′); 4.31 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.8 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.24 (ddq, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.7 Hz, J1′,4 = J1′,5 = J1′,3′ = 0.7 Hz, H-1′); 7.24 (dd, 1H, J5,4 = 8.0 Hz, J5,1′ = 0.6 Hz, H-5); 7.74 (dd, 1H, J4,5 = 8.0 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 13.38 (CH3S-2); 42.71 (CH2-2′); 63.72 (CH2-5′); 74.22 (CH-3′); 76.47 (CH-1′); 88.96 (CH-4′); 124.18 (CH-5); 136.32 (C-3); 136.36 (CH-4); 140.71 (C-6); 158.53 (C-2). IR spectrum (KBr): 3380, 3324, 3066, 1569, 1540, 1409, 1307, 1209, 1045, 948.
1β-[2-Methyl-6-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (20a). Me3Al (0.48 mL, 0.48 mmol, 2.0 equiv., 1 M in heptane) was added to a flame-dried flask containing a solution of 18a (130 mg, 0.24 mmol) and Pd(PPh3)4 (28 mg, 0.024 mmol, 10 mol%) in THF (3 mL). The mixture was stirred at 90 °C for 12 h, quenched by pouring into saturated NaH2PO4 (50 mL), and extracted with EtOAc (3 × 50 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 6% EtOAc in hexanes to give 20a (61 mg, 49%) as a colorless oil. HRMS (ESI) for C24H45NO3SSi2: [M + H] calculated, 484.2731; found, 484.2731. 1H NMR (500 MHz, CDCl3) 0.08 and 0.09 (2 × s, 2 × 6H, CH3Si); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.72 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.15 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.5 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.48 (s, 3H, CH3-2); 2.54 (s, 3H, CH3S-6); 3.67 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 5.2 Hz, H-5′a); 3.77 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.6 Hz, H-5′b); 3.94 (ddd, 1H, J4′,5′a = 5.2 Hz, J4′,5′b = 3.6 Hz, J4′,3′ = 2.3 Hz, H-4′); 4.41 (bdt, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.2 Hz, H-3′); 5.26 (bdd, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.5 Hz, H-1′); 6.99 (bd, 1H, J5,4 = 8.2 Hz, H-5); 7.68 (d, 1H, J4,5 = 8.2 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.48, −5.39, −4.69 and −4.64 (CH3Si); 13.52 (CH3S-6); 17.99 and 18.31 ((CH3)3C); 21.92 (CH3-2); 25.78 and 25.90 ((CH3)3C); 42.86 (CH2-2′); 63.50 (CH2-5′); 74.06 (CH-3′); 76.03 (CH-1′); 87.67 (CH-4′); 118.61 (CH-5); 131.61 (C-3); 133.44 (CH-4); 154.56 (C-2); 157.15 (C-6). IR spectrum (CCl4): 3062, 2956, 2897, 1583, 1560, 1472, 1450, 1408, 1389, 1373, 1361, 1315, 1258, 1098, 1088, 939, 838.
1β-[2-Methyl-6-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (20b). Compound 20b was prepared from 20a (54 mg, 0.11 mmol) by the general procedure to yield 20b (20 mg, 69%) as a white solid. HRMS (ESI) for C12H17NO3S: [M + H] calculated, 256.1002; found, 256.1002. 1H NMR (500 MHz, CD3OD): 1.84 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.4 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.28 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.5 Hz, J2′b,3′ = 1.8 Hz, H-2′b); 2.52 (s, 3H, CH3-2); 2.58 (s, 3H, CH3S-6); 3.66–3.72 (m, 2H, H-5′); 3.95 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.34 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 1.8 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.29 (bddq, 1H, J1′,2′a = 10.4 Hz, J1′,2′b = 5.5 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.6 Hz, H-1′); 7.22 (dt, 1H, J5,4 = 8.4 Hz, J5,LR = 0.6 Hz, H-5); 7.96 (bd, 1H, J4,5 = 8.4 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 13.92 (CH3S-6); 20.73 (CH3-2); 43.21 (CH2-2′); 63.78 (CH2-5′); 74.30 (CH-3′); 77.06 (CH-1′); 89.13 (CH-4′); 120.06 (CH-5); 133.70 (C-3); 137.11 (CH-4); 155.32 (C-2); 159.20 (C-6). IR spectrum (KBr): 3301, 2989, 2929, 2857, 1580, 1560, 1448, 1435, 1386, 1270, 1088, 1050, 1026.
1β-[6-Methyl-2-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (21a). Me3Al (0.40 mL, 0.40 mmol, 2.0 equiv., 1 M in heptane) was added to a flame-dried flask containing solution of 19a (103 mg, 0.20 mmol) and Pd(PPh3)4 (23 mg, 0.020 mmol, 10 mol%) in THF (2 mL). The mixture was stirred at 90 °C for 12 h, quenched by pouring into saturated NaH2PO4 (50 mL), and extracted with EtOAc (3 × 50 mL). The crude product was chromatographed on silica gel eluting with a gradient of hexanes to 5% EtOAc in hexanes to give 21a (53 mg, 58%) as a colorless oil. HRMS (ESI) for C24H45NO3SSi2: [M + H] calculated, 484.2731; found, 484.2732. 1H NMR (500 MHz, CDCl3) 0.08, 0.09 and 0.10 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.92 (2 × s, 2 × 9H, ((CH3)3C)); 1.69 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.4 Hz, J2′a,3′ = 5.7 Hz, H-2′a); 2.35 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.5 Hz, H-2′b); 2.48 (s, 3H, CH3-6); 2.58 (s, 3H, CH3S-2); 3.67 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 5.2 Hz, H-5′a); 3.78 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.7 Hz, H-5′b); 3.93 (ddd, 1H, J4′,5′a = 5.2 Hz, J4′,5′b = 3.7 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.38 (dtd, 1H, J3′,2′a = 5.7 Hz, J3′,4′ = J3′,2′b = 2.6 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.33 (bdd, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 5.8 Hz, H-1′); 6.82 (bd, 1H, J5,4 = 7.7 Hz, H-5); 7.66 (dd, 1H, J4,5 = 7.7 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.46, −5.39, −4.75 and −4.59 (CH3Si); 12.94 (CH3S-2); 18.01 and 18.32 ((CH3)3C); 24.09 (CH3-6); 25.80 and 25.91 ((CH3)3C); 42.06 (CH2-2′); 63.39 (CH2-5′); 73.86 (CH-3′); 75.41 (CH-1′); 87.41 (CH-4′); 118.46 (CH-5); 132.52 (CH-4); 132.99 (C-3); 154.61 (C-2); 156.42 (C-6). IR spectrum (CCl4): 3060, 2956, 2897, 1585, 1573, 1472, 1463, 1407, 1390, 1374, 1361, 1311, 1258, 1210, 1097, 1077, 1031, 971, 963, 939, 838.
1β-[6-Methyl-2-(methylsulfanyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (21b). Compound 21b was prepared from 21a (108 mg, 0.22 mmol) by the general procedure to yield 21b (46 mg, 81%) as a white solid. HRMS (ESI) for C12H17NO3S: [M + Na] calculated, 278.0821; found, 278.0822. 1H NMR (500 MHz, CD3OD): 1.73 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.1 Hz, H-2′a); 2.39 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 2.47 (s, 3H, CH3-6); 2.55 (s, 3H, CH3S-2); 3.66–3.72 (m, 2H, H-5′); 3.93 (td, 1H, J4′,5′a = J4′,5′b = 5.0 Hz, J4′,3′ = 2.8 Hz, H-4′); 4.30 (dddd, 1H, J3′,2′a = 6.1 Hz, J3′,4′ = 2.8 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.31 (bdd, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.7 Hz, H-1′); 6.94 (dt, 1H, J5,4 = 7.8 Hz, J5,LR = 0.6 Hz, H-5); 7.73 (dd, 1H, J4,5 = 7.8 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 13.15 (CH3S-2); 23.99 (CH3-6); 43.01 (CH2-2′); 63.84 (CH2-5′); 74.31 (CH-3′); 76.92 (CH-1′); 88.80 (CH-4′); 119.77 (CH-5); 133.88 (C-3); 134.17 (CH-4); 156.15 (C-2); 158.08 (C-6). IR spectrum (KBr): 3395, 3060, 2926, 1584, 1471, 1432, 1374, 1172, 1069, 1049, 963, 946, 911, 827, 722.
1β-(2-Chloro-6-ethynylpyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (22a). DMF (2 mL) and TMSA (35 μL, 0.25 mmol, 0.8 equiv.) were added through a septum to an argon-purged vial containing 4 (170 mg, 0.32 mmol), Pd(PPh3)2Cl2 (22 mg, 0.032 mmol), CuI (1 mg, 0.005 mmol) and Et3N (89 μL, 0.64 mmol). The resulting mixture was stirred at 60 °C for 12 h. The reaction mixture was then cooled and filtered on a pad of Celite and eluted with CHCl3. Solvents were then removed under vacuum, the crude product was dissolved in methanolic ammonia (28%, 10 mL) and the solution was stirred at rt for 1 h. The solvents were removed under vacuum, and the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 3% EtOAc in hexanes to give 22a (81 mg, 53% for two steps) as a colorless oil. A portion of starting material 4 (65 mg, 37%) was also isolated during chromatography. HRMS (ESI) for C24H40ClNO3Si2: [M + H] calculated, 482.2308; found, 482.2307. 1H NMR (500 MHz, CDCl3): 0.08, 0.086 and 0.093 (4 × s, 4 × 3H, CH3Si); 0.89 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.71 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.4 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.44 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 6.0 Hz, J2′b,3′ = 2.6 Hz, H-2′b); 3.16 (s, 1H, C[triple bond, length as m-dash]CH); 3.71 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.7 Hz, H-5′a); 3.77 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.4 Hz, H-5′b); 3.98 (ddd, 1H, J4′,5′a = 4.7 Hz, J4′,5′b = 3.4 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.38 (dtd, 1H, J3′,2′a = 5.6 Hz, J3′,4′ = J3′,2′b = 2.6 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.38 (bddq, 1H, J1′,2′a = 9.4 Hz, J1′,2′b = 6.0 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.39 (dd, 1H, J5,4 = 7.9 Hz, J5,1′ = 0.6 Hz, H-5); 8.01 (dd, 1H, J4,5 = 7.9 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.50, −5.42, −4.77 and −4.63 (CH3Si); 17.98 and 18.28 ((CH3)3C); 25.74 and 25.86 ((CH3)3C); 42.31 (CH2-2′); 63.20 (CH2-5′); 73.63 (CH-3′); 76.12 (CH-1′); 78.03 (C[triple bond, length as m-dash]CH); 81.51 (C[triple bond, length as m-dash]CH); 87.89 (CH-4′); 129.39 (CH-5); 135.96 (CH-4); 138.26 (C-3); 140.34 (C-6); 148.22 (C-2). IR spectrum (CCl4): 3309, 2956, 2898, 2123, 1582, 1546, 1472, 1463, 1441, 1390, 1361, 1336, 1258, 1174, 1097, 1060, 939, 838.
1β-(2-Chloro-6-ethynylpyridin-3-yl)-1,2-dideoxy-D-ribofuranose (22b). Compound 22b was prepared from 22a (91 mg, 0.19 mmol) by the general procedure to yield 22b (41 mg, 85%) as a yellow solid. HRMS (ESI) for C12H12ClNO3: [M − H] calculated, 252.0433; found, 252.0433. 1H NMR (500 MHz, CD3OD): 1.78 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 5.9 Hz, H-2′a); 2.50 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.8 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.69 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.72 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.5 Hz, H-5′b); 3.80 (s, 1H, CH[triple bond, length as m-dash]C); 3.99 (td, 1H, J4′,5′a = J4′,5′b = 4.7 Hz, J4′,3′ = 2.9 Hz, H-4′); 4.33 (bdt, 1H, J3′,2′a = 5.9 Hz, J3′,4′ = J3′,2′b = 2.4 Hz, H-3′); 5.37 (bddq, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.8 Hz, J1′,4 = J1′,5 = J1′,3′ = 0.5 Hz, H-1′); 7.53 (bd, 1H, J5,4 = 7.9 Hz, H-5); 8.14 (dd, 1H, J4,5 = 7.9 Hz, J4,1′ = 0.9 Hz, H-4). 13C NMR (125.7 MHz, CD3OD): 43.05 (CH2-2′); 63.67 (CH2-5′); 74.11 (CH-3′); 77.44 (CH-1′); 80.40 (CH[triple bond, length as m-dash]C); 82.12 (CH[triple bond, length as m-dash]C); 89.23 (CH-4′); 128.05 (CH-5); 138.01 (CH-4); 139.22 (C-3); 141.99 (C-6); 149.13 (C-2). IR spectrum (KBr): 3302, 3275, 2121, 1630, 1581, 1545, 1363, 1332, 1208, 1130, 1072, 1064, 1045, 995, 846.
1β-[2,6-Bis(trimethylsilylethynyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (23a). DMF (4 mL) and TMSA (360 μL, 2.6 mmol) were added through a septum to an argon-purged vial containing 4 (138 mg, 0.26 mmol), Pd(PPh3)2Cl2 (18 mg, 0.026 mmol), CuI (1 mg, 0.005 mmol) and Et3N (725 μL, 5.2 mmol). The resulting mixture was stirred at 90 °C for 12 h. The reaction mixture was then cooled and filtered on a pad of Celite and eluted with CHCl3. The solvents were removed under vacuum, and the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 1% EtOAc in hexanes to give 23a (150 mg, 95%) as a colorless oil. HRMS (ESI) for C32H57NO3Si4: [M + H] calculated, 616.3488; found, 616.3490. 1H NMR (500 MHz, CDCl3): 0.083, 0.085 and 0.089 (3 × s, 4 × 3H, CH3Si); 0.24 and 0.26 (2 × s, 2 × 9H, (CH3)3Si)); 0.90 and 0.91 (2 × s, 2 × 9H, ((CH3)3C)); 1.74 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 9.6 Hz, J2′a,3′ = 5.7 Hz, H-2′a); 2.41 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 6.0 Hz, J2′b,3′ = 2.3 Hz, H-2′b); 3.72 (dd, 1H, Jgem = 10.8 Hz, J5′a,4′ = 4.6 Hz, H-5′a); 3.77 (dd, 1H, Jgem = 10.8 Hz, J5′b,4′ = 3.4 Hz, H-5′b); 3.98 (ddd, 1H, J4′,5′a = 4.6 Hz, J4′,5′b = 3.4 Hz, J4′,3′ = 2.5 Hz, H-4′); 4.39 (dtd, 1H, J3′,2′a = 5.7 Hz, J3′,4′ = J3′,2′b = 2.4 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.54 (ddq, 1H, J1′,2′a = 9.6 Hz, J1′,2′b = 6.0 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.36 (dd, 1H, J5,4 = 8.1 Hz, J5,1′ = 0.7 Hz, H-5); 7.92 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.8 Hz, H-4). 13C NMR (125.7 MHz, CDCl3): −5.51, −5.41, −4.74 and −4.56 (CH3Si); −0.32 and −0.30 ((CH3)3Si); 18.37 and 18.32 ((CH3)3C); 25.88 and 25.90 ((CH3)3C); 43.17 (CH2-2′); 63.49 (CH2-5′); 74.07 (CH-3′); 76.82 (CH-1′); 88.06 (CH-4′); 94.68 and 100.17 (2 × C[triple bond, length as m-dash]CSi); 100.91 (C[triple bond, length as m-dash]CSi-2); 103.29 (C[triple bond, length as m-dash]CSi-6); 126.94 (CH-5); 133.37 (CH-4); 140.32 (C-2); 141.47 (C-3); 141.73 (C-6). IR spectrum (CCl4): 3067, 2958, 2899, 2161, 1576, 1553, 1472, 1463, 1444, 1408, 1390, 1362, 1258, 1252, 1232, 1097, 1031, 939, 846.
1β-(2,6-Bis(ethynyl)pyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (23b). Methanolic ammonia (25%, 10 mL) was added to a flask containing nucleoside 23a (287 mg, 0.47 mmol) and the mixture was stirred for 30 min at room temperature. Then the solvents were evaporated under vacuum and the crude product was chromatographed on silica gel in a gradient of hexanes to 6% EtOAc in hexanes to give 23b (167 mg, 76%) as a colorless oil. HRMS (ESI) for C26H41NO3Si2: [M + Na] calculated, 494.2517; found, 494.2516. 1H NMR (500 MHz, DMSO-d6): 0.07, 0.08 and 0.09 (4 × s, 4 × 3H, CH3Si); 0.86 and 0.89 (2 × s, 2 × 9H, (CH3)3C)); 1.76 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.2 Hz, H-2′a); 2.28 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.5 Hz, J2′b,3′ = 1.9 Hz, H-2′b); 3.61 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 6.1 Hz, H-5′a); 3.72 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 4.0 Hz, H-5′b); 3.88 (ddd, 1H, J4′,5′a = 6.1 Hz, J4′,5′b = 4.0 Hz, J4′,3′ = 1.9 Hz, H-4′); 4.37 (bdt, 1H, J3′,2′a = 5.2 Hz, J3′,4′ = J3′,2′b = 1.9 Hz, H-3′); 4.38 (s, 1H, CH[triple bond, length as m-dash]C-6); 4.67 (s, 1H, CH[triple bond, length as m-dash]C-2); 5.37 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.5 Hz, H-1′); 7.59 (bd, 1H, J5,4 = 8.1 Hz, H-5); 7.92 (dd, 1H, J4,5 = 8.1 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): −5.35, −5.27, −4.66 and −4.55 (CH3Si); 17.88 and 18.09 ((CH3)3C); 25.85 and 25.91 ((CH3)3C); 42.14 (CH2-2′); 63.32 (CH2-5′); 74.29 (CH-3′); 76.11 (CH-1′); 79.93 (CH[triple bond, length as m-dash]C-2); 80.78 (CH[triple bond, length as m-dash]C-2); 82.39 (CH[triple bond, length as m-dash]C-6); 85.52 (CH[triple bond, length as m-dash]C-6); 87.72 (CH-4′); 127.56 (CH-5); 134.11 (CH-4); 139.54 (C-2); 140.93 (C-6); 141.11 (C-3). IR spectrum (CCl4): 3309, 3066, 2956, 2897, 2115, 1579, 1554, 1472, 1463, 1445, 1406, 1390, 1361, 1275, 1258, 1180, 1098, 1083, 1006, 939, 838.
1β-[2,6-Bis(ethynyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (23c). Compound 23c was prepared from 23a (192 mg, 0.31 mmol) by the general procedure to yield 23c (51 mg, 67%) as an orange solid. HRMS (ESI) for C14H13NO3: [M + Na] calculated, 266.0788; found, 266.0786. 1H NMR (500 MHz, DMSO-d6): 1.68 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 10.2 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.26 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 1.8 Hz, H-2′b); 3.59 (m, 2H, H-5′); 3.84 (td, 1H, J4′,5′a = J4′,5′b = 4.9 Hz, J4′,3′ = 2.2 Hz, H-4′); 4.21 (m, 1H, H-3′); 4.36 (s, 1H, CH[triple bond, length as m-dash]C-6); 4.65 (s, 1H, CH[triple bond, length as m-dash]C-2); 4.83 (bt, 1H, JOH,5′a = JOH,5′b = 5.6 Hz, OH-5′); 5.17 (d, 1H, JOH,3′ = 3.8 Hz, OH-3′); 5.36 (bdd, 1H, J1′,2′a = 10.2 Hz, J1′,2′b = 5.7 Hz, H-1′); 7.59 (bd, 1H, J5,4 = 8.1 Hz, H-5); 8.01 (dd, 1H, J4,5 = 8.2 Hz, J4,1′ = 0.7 Hz, H-4). 13C NMR (125.7 MHz, DMSO-d6): 42.60 (CH2-2′); 62.31 (CH2-5′); 72.54 (CH-3′); 76.04 (CH-1′); 80.14 (CH[triple bond, length as m-dash]C-2); 80.63 (CH[triple bond, length as m-dash]C-6); 82.48 (CH[triple bond, length as m-dash]C-6); 85.35 (CH[triple bond, length as m-dash]C-2); 88.16 (CH-4′); 127.67 (CH-5); 134.56 (CH-4); 139.50 (C-2); 140.82 (C-6); 141.78 (C-3). IR spectrum (KBr): 3428, 3299, 3070, 2107, 1579, 1558, 1447, 1235, 1078, 1050, 1026, 846.
1β-[2-Chloro-6-(2-pyridyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (24a). DMF (2.5 mL) was added to a flame-dried and argon-purged flask, containing 4 (100 mg, 0.19 mmol), and PdCl2(PPh3)2 (7 mg, 0.0095 mmol, 5 mol%). After 5 min of stirring at room temperature, tributyl(2-pyridyl)stannane (0.25 mL, 0.76 mmol, 4.0 equiv.) was added, and mixture was heated to 100 °C for 12 h. The crude reaction mixture was diluted with Et2O (300 mL), washed with 2 M HCl (80 mL) and saturated NaHCO3 (100 mL). After evaporation of the solvents under reduced pressure, the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 3% EtOAc in hexanes to obtain 24a (82 mg, 82%) as a colorless oil. HRMS (ESI) for C27H43ClN2O3Si2: [M + H] calculated, 535.2574; found, 535.2574. 1H NMR (500 MHz, CDCl3): 0.098, 0.100, 0.107 and 0.109 (4 × s, 4 × 3H, CH3Si); 0.91 and 0.92 (2 × s, 2 × 9H, ((CH3)3C)); 1.77 (ddd, 1H, Jgem = 12.7 Hz, J2′a,1′ = 9.6 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.46 (ddd, 1H, Jgem = 12.7 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.4 Hz, H-2′b); 3.74 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.8 Hz, H-5′a); 3.81 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 4.00 (ddd, 1H, J4′,5′a = 4.8 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.42 (dtd, 1H, J3′,2′a = 5.7 Hz, J3′,4′ = J3′,2′b = 2.5 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.45 (ddq, 1H, J1′,2′a = 9.6 Hz, J1′,2′b = 5.9 Hz, J1′,3′ = J1′,4 = J1′,5 = 0.7 Hz, H-1′); 7.33 (dd, 1H, J5,4 = 7.5 Hz, J5,6 = 4.8 Hz, J5,3 = 1.2 Hz, H-5-py); 7.82 (td, 1H, J4,5 = J4,3 = 7.8 Hz, J4,6 = 1.8 Hz, H-4-py); 8.14 (dd, 1H, J4,5 = 8.0 Hz, J4,1′ = 0.8 Hz, H-4); 8.35 (bd, 1H, J5,4 = 8.0 Hz, H-5); 8.40 (dt, 1H, J3,4 = 8.0 Hz, J3,5 = J3,6 = 1.0 Hz, H-3-py); 8.67 (ddd, 1H, J6,5 = 4.8 Hz, J6,4 = 1.8 Hz, J6,3 = 0.9 Hz, H-6-py). 13C NMR (125.7 MHz, CDCl3): −5.47, −5.37, −4.75 and −4.62 (CH3Si); 18.00 and 18.31 ((CH3)3C); 25.77 and 25.90 ((CH3)3C); 42.47 (CH2-2′); 63.30 (CH2-5′); 73.76 (CH-3′); 76.30 (CH-1′); 87.89 (CH-4′); 119.89 (CH-5); 121.43 (CH-3-py); 124.06 (CH-5-py); 136.73 (CH-4); 137.21 (CH-4-py); 137.65 (C-3); 147.92 (C-2); 148.96 (CH-6-py); 154.50 (C-2-py); 154.79 (C-6). IR spectrum (CCl4): 2956, 2897, 1588, 1568, 1472, 1463, 1445, 1390, 1361, 1340, 1258, 1218, 1174, 1071, 1054, 939, 838.
1β-[2-Chloro-6-(2-pyridyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (24b). Compound 24b was prepared from 24a (207 mg, 0.39 mmol) by the general procedure to yield 24b (102 mg, 86%) as a white solid. HRMS (ESI) for C15H15ClN2O3: [M + H] calculated, 307.0844; found, 307.0844. 1H NMR (500 MHz, CD3OD): 1.84 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.54 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.72 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.75 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.5 Hz, H-5′b); 4.01 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.36 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.44 (ddq, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.7 Hz, J1′,4 = J1′,5 = = J1′,3′ = 0.7 Hz, H-1′); 7.46 (ddd, 1H, J5,4 = 7.6 Hz, J5,6 = 4.9 Hz, J5,3 = 1.2 Hz, H-5-py); 7.96 (ddd, 1H, J4,3 = 8.0 Hz, J4,5 = 7.6 Hz, J4,6 = 1.8 Hz, H-4-py); 8.25 (dd, 1H, J4,5 = 8.0 Hz, J4,1′ = 0.8 Hz, H-4); 8.30 (bd, 1H, J5,4 = 8.0 Hz, H-5); 8.35 (dt, 1H, J3,4 = 8.0 Hz, J3,5 = J3,6 = 1.1 Hz, H-3-py); 8.65 (ddd, 1H, J6,5 = 4.9 Hz, J6,4 = 1.8 Hz, J6,3 = 0.9 Hz, H-6-py). 13C NMR (125.7 MHz, CD3OD): 43.20 (CH2-2′); 63.76 (CH2-5′); 74.19 (CH-3′); 77.64 (CH-1′); 89.22 (CH-4′); 121.14 (CH-5); 122.68 (CH-3-py); 125.72 (CH-5-py); 138.33 (CH-4); 138.80 (C-3); 139.05 (CH-4-py); 149.22 (C-2); 150.14 (CH-6-py); 155.57 (C-2-py); 156.02 (C-6). IR spectrum (KBr): 3420, 3336, 3096, 3066, 1587, 1573, 1547, 1478, 1434, 1256, 1173, 1149, 993, 1063, 1047, 993.
1β-[2,6-Bis(2-pyridyl)pyridin-3-yl]-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (25a). Toluene (3.0 mL) was added to a flame-dried and argon-purged flask, containing 4 (159 mg, 0.29 mmol), and Pd(PPh3)4 (65 mg, 0.058 mmol, 20 mol%). After 5 min of stirring at room temperature, tributyl(2-pyridinyl)stannane (0.38 mL, 1.16 mmol, 4.0 equiv.) was added, and the mixture was heated to 110 °C for 12 h. The crude reaction mixture was diluted with Et2O (300 mL), and washed with 2 M HCl (80 mL) and saturated NaHCO3 (100 mL). After evaporation of the solvents under reduced pressure, the crude product was chromatographed on silica gel eluting with a gradient of hexanes to 12% EtOAc in hexanes to obtain 25a (197 mg, 92%) as a colorless oil. HRMS (ESI) for C32H47N3O3Si2: [M + H] calculated, 578.3229; found, 578.3229. 1H NMR (500 MHz, CDCl3): 0.08, 0.09, 0.11 and 0.13 (4 × s, 4 × 3H, CH3Si); 0.90 and 0.93 (2 × s, 2 × 9H, ((CH3)3C)); 1.91 (ddd, 1H, Jgem = 12.8 Hz, J2′a,1′ = 10.0 Hz, J2′a,3′ = 5.6 Hz, H-2′a); 2.50 (ddd, 1H, Jgem = 12.8 Hz, J2′b,1′ = 5.4 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.73 (dd, 1H, Jgem = 10.7 Hz, J5′a,4′ = 5.2 Hz, H-5′a); 3.81 (dd, 1H, Jgem = 10.7 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.93 (ddd, 1H, J4′,5′a = 5.2 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.3 Hz, H-4′); 4.42 (bdt, 1H, J3′,2′a = 5.5 Hz, J3′,4′ = J3′,2′b = 2.2 Hz, H-3′); 5.74 (bdd, 1H, J1′,2′a = 10.0 Hz, J1′,2′b = 5.4 Hz, H-1′); 7.33 (dd, 1H, J5,4 = 7.6 Hz, J5,6 = 4.9 Hz, J5,3 = 1.2 Hz, H-5-py-2); 7.39 (m, 1H, H-5-py-6); 7.87 (td, 1H, J4,5 = J4,3 = 7.7 Hz, J4,6 = 1.2 Hz, H-4-py-2); 7.91 (H-4-py-6); 8.11 (dt, 1H, J3,4 = 7.9 Hz, J3,5 = J3,6 = 1.1 Hz, H-3-py-2); 8.36 (bd, 1H, J4,5 = 8.3 Hz, H-4); 8.53 (bd, 1H, J5,4 = 8.3 Hz, H-5); 8.58 (bd, 1H, J3,4 = 8.0 Hz, H-3-py-6); 8.67 (ddd, 1H, J6,5 = 4.9 Hz, J6,4 = 1.9 Hz, J6,3 = 1.0 Hz, H-6-py-2); 8.75 (ddd, 1H, J6,5 = 5.0 Hz, J6,4 = 1.7 Hz, J6,3 = 0.8 Hz, H-6-py-6). 13C NMR (125.7 MHz, CDCl3): −5.46, −5.33, −4.77 and −4.65 (CH3Si); 17.98 and 18.34 ((CH3)3C); 25.76 and 25.93 ((CH3)3C); 44.75 (CH2-2′); 63.65 (CH2-5′); 74.42 (CH-3′); 76.58 (CH-1′); 87.92 (CH-4′); 121.11 (CH-5); 121.95 (CH-3-py-6); 122.89 (CH-5-py-2); 123.89 (CH-5-py-6); 124.54 (CH-3-py-2); 136.57 (CH-4); 136.74 (CH-4-py-2); 138.4 (CH-4-py-6); 138.77 (C-3); 147.89 (CH-6-py-2,6); 152.35 (C-6); 153.65 (C-2); 155.12 (C-2-py-6); 157.91 (C-2-py-2). IR spectrum (CCl4): 3088, 3065, 2956, 2929, 2897, 285, 7, 1590, 1586, 1577, 1566, 1556, 1472, 1462, 1456, 1434, 1425, 1389, 1361, 1257, 1173, 1147, 1095, 1040, 1031, 1006, 939, 838.
1β-[2,6-Bis(2-pyridyl)pyridin-3-yl]-1,2-dideoxy-D-ribofuranose (25b). Compound 25b was prepared from 25a (209 mg, 0.36 mmol) by the general procedure to yield 25b (110 mg, 87%) as a white solid. HRMS (ESI) for C20H19N3O3: [M + H] calculated, 350.1499; found, 350.1498. 1H NMR (500 MHz, CD3OD): 1.94 (ddd, 1H, Jgem = 13.3 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.2 Hz, H-2′a); 2.35 (ddd, 1H, Jgem = 13.3 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.72 (dd, 1H, Jgem = 11.7 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.74 (dd, 1H, Jgem = 11.7 Hz, J5′b,4′ = 4.5 Hz, H-5′b); 3.89 (btd, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.9 Hz, H-4′); 4.30 (dddd, 1H, J3′,2′a = 6.2 Hz, J3′,4′ = 2.9 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.6 Hz, H-3′); 5.62 (dd, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.7 Hz, H-1′); 7.44 (ddd, 1H, J5,4 = 7.5 Hz, J5,6 = 4.9 Hz, J5,3 = 1.2 Hz, H-5-py-6); 7.48 (m, 1H, H-5-py-2); 7.93 (ddd, 1H, J4,3 = 8.0 Hz, J4,5 = 7.5 Hz, J4,6 = 1.8 Hz, H-4-py-6); 7.98–8.01 (m, 2H, H-3,4-py-2); 8.38 (bd, 1H, J5,4 = 8.3 Hz, H-5); 8.40 (bd, 1H, J4,5 = 8.3 Hz, H-4); 8.46 (dt, 1H, J3,4 = 8.0 Hz, J3,5 = J3,6 = 1.1 Hz, H-3-py-6); 8.65 (ddd, 1H, J6,5 = 4.9 Hz, J6,4 = 1.8 Hz, J6,3 = 0.9 Hz, H-6-py-6); 8.68 (dt, 1H, J6,5 = 4.9 Hz, J6,4 = J6,3 = 1.4 Hz, H-6-py-2). 13C NMR (125.7 MHz, CD3OD): 45.16 (CH2-2′); 63.87 (CH2-5′); 74.36 (CH-3′); 77.73 (CH-1′); 89.01 (CH-4′); 121.89 (CH-5); 122.68 (CH-3-py-6); 124.62 (CH-5-py-2); 125.31 (CH-5-py-6); 125.85 (CH-3-py-2); 137.62 (CH-4); 138.47 (CH-4-py-2); 138.73 (CH-4-py-6); 138.91 (C-3); 149.38 (CH-6-py-2); 150.11 (CH-6-py-6); 155.26 (C-6); 155.51 (C-2); 157.08 (C-2-py-6); 159.27 (C-2-py-2). IR spectrum (KBr): 3415, 3088, 3062, 2929, 1590, 1575, 1565, 1557, 1473, 1455, 1434, 1425, 1353, 1254, 1201, 1174, 1150, 1095, 1071, 1050, 1021, 942, 855.
1β-(2-Chloropyridin-3-yl)-1,2-dideoxy-3,5-di-O-(t-butyldimethylsilyl)-D-ribofuranose (26a). Vinylmagnesium chloride (1 M solution in THF, 1 mL, 1.0 mmol) was added dropwise to a flame-dried flask containing a solution of the nucleoside 4 (100 mg, 0.19 mmol) and Fe(acac)3 (13 mg, 0.038 mmol) in dry THF (3.0 mL) under Ar. The reaction mixture was then stirred at rt for 12 h. Then the mixture was poured onto a mixture of ice (100 mL) and NH4Cl (1 g), and extracted with chloroform (3 × 100 mL). Evaporation of the organic phase followed by column chromatography on silica gel eluting with a gradient of hexanes to 4% EtOAc in hexanes afforded the nucleoside 26a (40 mg, 47%) as a colorless oil. HRMS (ESI) for C22H40ClNO3Si2: [M + Na] calculated, 480.2128; found, 480.2126. 1H NMR (500 MHz, CDCl3): 0.086, 0.088, 0.090 and 0.10 (4 × s, 4 × 3H, CH3Si); 0.89 and 0.92 (2 × s, 2 × 9H, ((CH3)3C); 1.73 (ddd, 1H, Jgem = 12.6 Hz, J2′a,1′ = 9.5 Hz, J2′a,3′ = 5.5 Hz, H-2′a); 2.44 (ddd, 1H, Jgem = 12.6 Hz, J2′b,1′ = 5.9 Hz, J2′b,3′ = 2.5 Hz, H-2′b); 3.71 (dd, 1H, Jgem = 10.9 Hz, J5′a,4′ = 4.8 Hz, H-5′a); 3.78 (dd, 1H, Jgem = 10.9 Hz, J5′b,4′ = 3.5 Hz, H-5′b); 3.99 (ddd, 1H, J4′,5′a = 4.8 Hz, J4′,5′b = 3.5 Hz, J4′,3′ = 2.6 Hz, H-4′); 4.39 (dt, 1H, J3′,2′a = 5.5 Hz, J3′,4′ = J3′,2′b = 2.6 Hz, H-3′); 5.40 (dd, 1H, J1′,2′a = 9.5 Hz, J1′,2′b = 5.9 Hz, H-1′); 7.23 (dd, 1H, J5,4 = 7.7 Hz, J5,6 = 4.6 Hz, H-5); 8.03 (dd, 1H, J4,5 = 7.6 Hz, J4,6 = 1.3 Hz, H-4); 8.28 (bd, 1H, J6,5 = 4.6 Hz, H-6). 13C NMR (125.7 MHz, CDCl3): −5.49, −5.42, −4.76 and −4.62 (CH3Si); 17.99 and 18.28 ((CH3)3C); 25.75 and 25.86 ((CH3)3C); 42.32 (CH2-2′); 63.28 (CH2-5′); 73.71 (CH-3′); 76.14 (CH-1′); 87.82 (CH-4′); 122.68 (CH-5); 135.86 (CH-4); 137.67 (C-3); 147.93 (CH-6); 148.50 (C-2). IR spectrum (CCl4): 2956, 2899, 1582, 1566, 1472, 1463, 1449, 1390, 1362, 1336, 1258, 1209, 1172, 1057, 1031, 1006, 968, 838.
1β-(2-Chloropyridin-3-yl)-1,2-dideoxy-D-ribofuranose (26b). Compound 26b was prepared from 26a (80 mg, 0.17 mmol) by the general procedure to yield 26b (32 mg, 82%) as a white solid. HRMS (ESI) for C10H12ClNO3: [M + Na] calculated, 252.0398; found, 252.0398. 1H NMR (500 MHz, CD3OD): 1.78 (ddd, 1H, Jgem = 13.1 Hz, J2′a,1′ = 10.1 Hz, J2′a,3′ = 6.0 Hz, H-2′a); 2.50 (ddd, 1H, Jgem = 13.1 Hz, J2′b,1′ = 5.7 Hz, J2′b,3′ = 2.0 Hz, H-2′b); 3.70 (dd, 1H, Jgem = 11.8 Hz, J5′a,4′ = 5.0 Hz, H-5′a); 3.72 (dd, 1H, Jgem = 11.8 Hz, J5′b,4′ = 4.6 Hz, H-5′b); 3.99 (td, 1H, J4′,5′a = J4′,5′b = 4.8 Hz, J4′,3′ = 2.7 Hz, H-4′); 4.33 (dddd, 1H, J3′,2′a = 6.0 Hz, J3′,4′ = 2.7 Hz, J3′,2′b = 2.0 Hz, J3′,1′ = 0.7 Hz, H-3′); 5.38 (ddpent, 1H, J1′,2′a = 10.1 Hz, J1′,2′b = 5.7 Hz, J1′,4 = J1′,5 = J1′,6 = J1′,3′ = 0.7 Hz, H-1′); 7.41 (ddd, 1H, J5,4 = 7.7 Hz, J5,6 = 4.8 Hz, J5,1′ = 0.6 Hz, H-5); 8.17 (ddd, 1H, J4,5 = 7.7 Hz, J4,6 = 2.0 Hz, J4,1′ = 0.8 Hz, H-4); 8.27 (ddd, 1H, J6,5 = 4.8 Hz, J6,4 = 2.0 Hz, J6,1′ = 0.5 Hz, H-6). 13C NMR (125.7 MHz, CD3OD): 43.11 (CH2-2′); 63.72 (CH2-5′); 74.13 (CH-3′); 77.46 (CH-1′); 89.17 (CH-4′); 124.54 (CH-5); 137.86 (CH-4); 138.87 (C-3); 149.10 (CH-6); 149.33 (C-2). IR spectrum (KBr): 3359, 1630, 1580, 1571, 1450, 1442, 1389, 1181, 1073, 1063, 1043, 1023, 951.

Crystallographic data for 4

M = 308.55 g mol−1, monoclinic system, space group P21, a = 8.9755 (9) Å, b = 6.9472 (5) Å, c = 9.1777 (9) Å, β = 90.968 (9)°, Z = 2, V = 572.19 (9) Å3, Dc = 1.791 g cm−3, μ(Cu-Kα) = 7.002 mm−1, crystal dimensions of 0.58 × 0.56 × 0.21 mm. Data were collected at 170 (2) K on an Xcalbur Onyx CCD diffractometer with graphite monochromated Cu-Kα radiation. The structure was solved by charge flipping methods18 using the CRYSTALS suite of programs19 and anisotropically refined by full matrix least squares on F value to final R = 0.036 and Rw = 0.042 using 2220 independent reflections (Θmax = 77.3°) and 147 parameters. The absolute configuration on stereogenic centers was confirmed by refinement of the Flack parameter (resulting value −0.02 (2)). The structure was deposited into the Cambridge Structural Database under number CCDC 927315.

Crystallographic data for 8b

M = 243.69 g mol−1, monoclinic system, space group P21, a = 5.3111 (3) Å, b = 11.1077 (6) Å, c = 19.5383 (13) Å, β = 96.676 (6)°, Z = 4, V = 1144.84 (12) Å3, Dc = 1.414 g cm−3, μ(Cu-Kα) = 2.908 mm−1, crystal dimensions of 0.49 × 0.37 × 0.26 mm. Data were collected at 190 (2) K on an Xcalbur Onyx CCD diffractometer with graphite monochromated Cu-Kα radiation. The structure was solved by charge flipping methods1 using the CRYSTALS suite of programs2 and anisotropically refined by full matrix least squares on F squared value to final R = 0.038 and Rw = 0.095 using 4688 independent reflections (Θmax = 77.4°) and 291 parameters. The absolute configuration on stereogenic centers was confirmed by refinement of the Flack parameter (resulting value −0.008 (12)). The structure was deposited into the Cambridge Structural Database under number CCDC 927314.

Acknowledgements

This work was supported by institutional support from the Academy of Sciences of the Czech Republic (RVO: 61388963) and Charles University, by a grant from the Czech Science Foundation (P207/11/0344) and by Gilead Sciences, Inc. The authors thank Mrs Eva Tloušťová (IOCB) for cytostatic and Dr Y.-J. Lee and Dr G. Bahador (Gilead Sciences, Inc.) for anti-HCV screening.

Notes and references

  1. Reviews: (a) J. Štambaský, M. Hocek and P. Kočovský, Chem. Rev., 2009, 109, 6729–6764 CrossRef; (b) M. F. A. Adamo and R. Pergoli, Curr. Org. Chem., 2008, 12, 1544–1569 CrossRef CAS; (c) Q. P. Wu and C. Simons, Synthesis, 2004, 1533–1553 CrossRef CAS.
  2. (a) A. M. Leconte, G. T. Hwang, S. Matsuda, P. Capek, Y. Hari and F. E. Romesberg, J. Am. Chem. Soc., 2008, 130, 2336–2343 CrossRef CAS; (b) D. A. Malyshev, Y. J. Seo, P. Ordoukhanian and F. E. Romesberg, J. Am. Chem. Soc., 2009, 131, 14620–14621 CrossRef CAS; (c) Y. J. Seo, D. A. Malyshev, T. Lavergne, P. Ordoukhanian and F. E. Romesberg, J. Am. Chem. Soc., 2011, 133, 19878–19888 CrossRef CAS; (d) D. A. Malyshev, K. Dhami, H. T. Quach, T. Lavergne, P. Ordoukhanian and F. E. Romesberg, Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 12005–12010 CrossRef CAS; (e) K. Betz, D. A. Malyshev, T. Lavergne, W. Welte, K. Diederichs, T. J. Dwyer, P. Ordoukhanian, F. E. Romesberg and A. Marx, Nat. Chem., 2012, 8, 612–614 CrossRef CAS.
  3. (a) M. Urban, N. Joubert, M. Hocek, R. E. Alexander and R. D. Kuchta, Biochemistry, 2009, 48, 10866–10881 CrossRef CAS; (b) M. Urban, N. Joubert, B. Purse, M. Hocek and R. Kuchta, Biochemistry, 2010, 49, 727–735 CrossRef CAS; (c) T. Lund, N. Cavanaugh, N. Joubert, M. Urban, J. Patro, M. Hocek and R. D. Kuchta, Biochemistry, 2011, 50, 7243–7250 CrossRef CAS.
  4. (a) M. Hocek, R. Pohl and B. Klepetářová, Eur. J. Org. Chem., 2005, 4525–4528 CrossRef CAS; (b) M. Urban, R. Pohl, B. Klepetářová and M. Hocek, J. Org. Chem., 2006, 71, 7322–7328 CrossRef CAS; (c) N. Joubert, R. Pohl, B. Klepetářová and M. Hocek, J. Org. Chem., 2007, 72, 6797–6805 CrossRef CAS; (d) M. Štefko, L. Slavětínská, B. Klepetářová and M. Hocek, J. Org. Chem., 2010, 75, 442–449 CrossRef; (e) M. Štefko, L. Slavětínská, B. Klepetářová and M. Hocek, J. Org. Chem., 2011, 76, 6619–6635 CrossRef; (f) H. Chapuis, N. Joubert, T. Kubelka, R. Pohl and M. Hocek, Eur. J. Org. Chem., 2012, 1759–1767 CrossRef CAS.
  5. T. Lavergne, M. Degardin, D. A. Malyshev, H. T. Qyach, K. Dhami, P. Ordoukhanian and F. E. Romesberg, J. Am. Chem. Soc., 2013, 135, 5408–5419 CrossRef CAS.
  6. (a) T. Kubelka, L. Slavětínská, B. Klepetářová and M. Hocek, Eur. J. Org. Chem., 2010, 2666–2669 CrossRef CAS; (b) T. Kubelka, L. Slavětínská and M. Hocek, Synthesis, 2012, 953–965 CAS.
  7. General review on regio- and chemoselective cross-couplings of dihaloaromatics: S. Schöter, C. Stock and T. Bach, Tetrahedron, 2005, 61, 2245–2267 CrossRef.
  8. Review on selective dihalopyridine cross-couplings: (a) R. Rossi, F. Bellina and M. Lessi, Adv. Synth. Catal., 2012, 354, 1181–1255 CrossRef CAS . Examples: ; (b) S. Rádl, P. Hezký, W. Hafner, M. Buděšínský and L. Hejnová, Bioorg. Med. Chem. Lett., 2000, 10, 55–58 CrossRef; (c) F. Cottet and M. Schlosser, Eur. J. Org. Chem., 2002, 327–330 CrossRef CAS; (d) D. C. Blakemore and L. A. Marples, Tetrahedron Lett., 2011, 52, 4192–4195 CrossRef CAS.
  9. M. A. Cameron, S. B. Cush and R. P. Hammer, J. Org. Chem., 1997, 62, 9065 CrossRef CAS.
  10. X. Huang and S. L. Buchwald, Org. Lett., 2001, 3, 3417–3419 CrossRef CAS.
  11. M. Štefko and M. Hocek, Synthesis, 2010, 4199 Search PubMed.
  12. P. Ji, J. H. Atherton and M. I. Page, J. Org. Chem., 2012, 77, 7471 CrossRef CAS.
  13. Y. Fukuda and K. Utimoto, J. Org. Chem., 1991, 56, 3729–3731 CrossRef CAS.
  14. Review: (a) G. H. Clever, C. Kaul and T. Carell, Angew. Chem., Int. Ed., 2007, 46, 6226–6236 CrossRef CAS ; relevant examples: ; (b) D. Shin and C. Switzer, Chem. Commun., 2007, 4401–4403 RSC; (c) C. Switzer, S. Sinha, P. H. Kim and B. D. Heuberger, Angew. Chem., Int. Ed., 2005, 44, 1529–1532 CrossRef CAS; (d) C. Brotschi, A. Haberli and C. J. Leumann, Angew. Chem., Int. Ed., 2001, 40, 3012–3014 CrossRef CAS; (e) H. Weizman and Y. Tor, J. Am. Chem. Soc., 2001, 123, 3375–3376 CrossRef CAS.
  15. A. Fürstner, A. Leitner, M. Mendez and H. Krause, J. Am. Chem. Soc., 2002, 124, 13856–13863 CrossRef.
  16. D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff and M. R. Boyd, Cancer Res., 1988, 48, 4827–4833 CAS.
  17. (a) V. Lohmann, F. Korner, J. O. Koch, U. Herian, L. Theilmann and R. Bartenschlager, Science, 1999, 285, 110–113 CrossRef CAS; (b) L. J. Stuyver, T. Whitaker, T. R. McBrayer, B. I. Hernandez-Santiago, S. Lostia, P. M. Tharnish, M. Ramesh, C. K. Chu, R. Jordan, J. X. Shi, S. Rachakonda, K. A. Watanabe, M. J. Otto and R. F. Schinazi, Antimicrob. Agents Chemother., 2003, 47, 244–254 CrossRef CAS.
  18. L. Palatinus and G. Chapuis, J. Appl. Crystallogr., 2007, 40, 786–790 CrossRef CAS.
  19. P. W. Betteridge, J. R. Carruthers, R. I. Cooper, K. Prout and D. J. Watkin, J. Appl. Crystallogr., 2003, 36, 1487–1487 CrossRef CAS.

Footnote

Electronic supplementary information (ESI) available: Copies of all NMR spectra. CCDC 927314 and 927315. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c3ob40774h

This journal is © The Royal Society of Chemistry 2013
Click here to see how this site uses Cookies. View our privacy policy here.